



US 20020102263A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2002/0102263 A1**
Wands et al. (43) **Pub. Date: Aug. 1, 2002**

(54) **DIAGNOSIS AND TREATMENT OF
MALIGNANT NEOPLASMS**

(76) Inventors: **Jack R. Wands**, Waban, MA (US);
Suzanne M. de la Monte, East
Greenwich, RI (US); **Nedim Ince**,
Boston, MA (US); **Rolf I. Carlson**,
Boston, MA (US)

Correspondence Address:

**MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.**
One Financial Center
Boston, MA 02111 (US)

(21) Appl. No.: **09/903,248**

(22) Filed: **Jul. 11, 2001**

Related U.S. Application Data

(62) Division of application No. 09/436,184, filed on Nov.
8, 1999.

Publication Classification

(51) **Int. Cl.⁷** **G01N 33/574**; A61K 39/395
(52) **U.S. Cl.** **424/155.1**; 435/7.23

(57) **ABSTRACT**

The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.

Fig. 1




Fig. 2




Fig. 3a





Fig. 3b






Fig. 4

Fig. 5b




Fig. 5d




Fig. 5a




Fig. 5c





Fig. 6

Fig. 7




Fig. 8





Fig. 9

DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

[0001] This invention was made with U.S. Government support under National Institutes of Health grants CA-35711, AA-02666, AA-02169, and AA11431. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0002] Primary malignant central nervous system (CNS) neoplasms, particularly glioblastomas, are highly fatal due to their aggressive and widespread infiltration of the brain and resistance to anti-cancer treatments. Although progress has been made in unraveling the pathological mechanisms underlying CNS cancers as well as other cancer types, tumor specific therapeutic approaches and methods of diagnosis have been largely elusive.

SUMMARY OF THE INVENTION

[0003] The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to a human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex. Malignant neoplasms detected in this manner include those derived from endodermal tissue, e.g., colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts. Neoplasms of the central nervous system (CNS) such as primary malignant CNS neoplasms of both neuronal and glial cell origin and metastatic CNS neoplasms are also detected. Patient derived tissue samples, e.g., biopsies of solid tumors, as well as bodily fluids such as a CNS-derived bodily fluid, blood, serum, urine, saliva, sputum, lung effusion, and ascites fluid, are contacted with an HAAH-specific antibody.

[0004] The assay format is also useful to generate temporal data used for prognosis of malignant disease. A method for prognosis of a malignant neoplasm of a mammal is carried out by (a) contacting a bodily fluid from the mammal with an antibody which binds to an HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex; (b) quantitating the amount of complex to determine the level of HAAH in the fluid; and (c) comparing the level of HAAH in the fluid with a normal control level of HAAH. An increasing level of HAAH over time indicates a progressive worsening of the disease, and therefore, an adverse prognosis.

[0005] The invention also includes an antibody which binds to HAAH. The antibody preferably binds to a site in the carboxyterminal catalytic domain of HAAH. Alternatively, the antibody binds to an epitope that is exposed on the surface of the cell. The antibody is a polyclonal antisera or monoclonal antibody. The invention encompasses not only an intact monoclonal antibody, but also an immunologically-active antibody fragment, e.g., a Fab or (Fab)₂ fragment; an engineered single chain Fv molecule; or a chimeric molecule, e.g., an antibody which contains the binding specificity of one antibody, e.g., of murine origin, and the

remaining portions of another antibody, e.g., of human origin. Preferably the antibody is a monoclonal antibody such as FB50, 5C7, 5E9, 19B, 48A, 74A, 78A, 86A, HA238A, HA221, HA 239, HA241, HA329, or HA355. Antibodies which bind to the same epitopes as those monoclonal antibodies are also within the invention.

[0006] An HAAH-specific intrabody is a recombinant single chain HAAH-specific antibody that is expressed inside a target cell, e.g., tumor cell. Such an intrabody binds to endogenous intracellular HAAH and inhibits HAAH enzymatic activity or prevents HAAH from binding to an intracellular ligand. HAAH-specific intrabodies inhibit intracellular signal transduction, and as a result, inhibit growth of tumors which overexpress HAAH.

[0007] A kit for diagnosis of a tumor in a mammal contains an HAAH-specific antibody. The diagnostic assay kit is preferentially formulated in a standard two-antibody binding format in which one HAAH-specific antibody captures HAAH in a patient sample and another HAAH-specific antibody is used to detect captured HAAH. For example, the capture antibody is immobilized on a solid phase, e.g., an assay plate, an assay well, a nitrocellulose membrane, a bead, a dipstick, or a component of an elution column. The second antibody, i.e., the detection antibody, is typically tagged with a detectable label such as a calorimetric agent or radioisotope.

[0008] Also within the invention is a method of inhibiting tumor growth in a mammal, which is carried out by administering to the mammal a compound which inhibits expression or enzymatic activity of HAAH. Preferably, the compound is substantially pure nucleic acid molecule such as an HAAH antisense DNA, the sequence of which is complementary to a coding sequence of HAAH. Expression of HAAH is inhibited by contacting mammalian cells, e.g., tumor cells, with HAAH antisense DNA or RNA, e.g., a synthetic HAAH antisense oligonucleotide. For example, HAAH antisense nucleic acid is introduced into glioblastoma cells or other tumor cells which overexpress HAAH. Binding of the antisense nucleic acid to an HAAH transcript in the target cell results in a reduction in HAAH production by the cell. By the term "antisense nucleic acid" is meant a nucleic acid (RNA or DNA) which is complementary to a portion of an mRNA, and which hybridizes to and prevents translation of the mRNA. Preferably, the antisense DNA is complementary to the 5' regulatory sequence or the 5' portion of the coding sequence of HAAH mRNA (e.g., a sequence encoding a signal peptide or a sequence within exon 1 of the HAAH gene). Standard techniques of introducing antisense DNA into the cell may be used, including those in which antisense DNA is a template from which an antisense RNA is transcribed. The method is to treat tumors in which expression of HAAH is upregulated, e.g., as a result of malignant transformation of the cells. The length of the oligonucleotide is at least 10 nucleotides and may be as long as the naturally occurring HAAH transcript. Preferably, the length is between 10 and 50 nucleotides, inclusive. More preferably, the length is between 10 and 20 nucleotides, inclusive.

[0009] By "substantially pure DNA or RNA" is meant that the nucleic acid is free of the genes which, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank a HAAH gene. The term

therefore includes, for example, a recombinant nucleic acid which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a procaryote or eucaryote at a site other than its natural site; or which exists as a separate molecule (e.g., a cDNA or a

HAAH and inhibit intracellular HAAH enzymatic activity, e.g., by binding to an epitope in the catalytic domain of HAAH. Other compounds such as L-mimosine or hydroxypyridone are administered directly into a tumor site or systemically to inhibit HAAH hydroxylase activity.

TABLE 1

Amino acid sequence of HAAH			
MAQRKNAKSS	GNSSSSGSGS	GSTSAGSSSP	GARRETKHGG HKNGRKGLS GTSFFTWMFV 61
IALLGVWTSV	AVVWFDLVDY	EEVLGKLGIV	DADGDGDFDV DDAKVLLGLK ERSTSEPAVP 121
PEEAEPHTEP	EEQVPVEAEP	QNIEDEAKEQ	IQSLLHEMVH AEHVEGEDLQ QEDGPTGEPQ 181
QEDDEFLMAT	DVDDRFBETL	PEVSHEETEH	SYHVEETVSQ DCNQDMEEMM SEQENPDSSE 241
PVVEDERLHH	DTDDVTYQVY	EEQAVYEPL	NEGIEITEVT APPEDNPVED SQVIVEEVS I 301
FPVEEQQVEP	PETNRKTDDP	EQKAKVKKKK	PKLLNKFDKT IKAELDAAEK LRKRGKIEEA 361
VNAFKELVRK	YPQSPRARYG	KAQCEDDLAE	KRRSNEVLRG AIETYQEVAS LPDVPADLLK 421
LSLKRRSDRQ	QFLGHMRGSL	LTLQRLVQLF	PNDTSLKNDL GVGYLLIGDN DNAKKVYEEV 481
LSVTPNDGFA	KVHYGFILKA	QNKIAESIPY	LKEGIESGDP GTDDGRFYFH LGDAMQRVGN 541
KEAYKWYELG	HKRGHFASVW	QRSLYNVNGL	KAQPWWTPKE TGYTELVKSL ERNWKLIRDE 601
GLAVMDKAKG	LFLPEDENLR	EKGDSQFTL	WQQGRRNENA CKGAPKTCTL LEKFPETTGC 661
RRGQIKYSIM	HPGTHVWPHT	GPTNCRLRMH	LGLVIPKEGC KIRCANETRT WEEGKVLIFD 721
DSFEHEVWQD	ASSFRLIFIV	DVWHPELTPQ	QRRSLPAI

(SEQ ID NO:2; GENBANK Accession No. S83325; His motif is underlined; conserved sequences within the catalytic domain are designated by bold type)

genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant nucleic acid which is part of a hybrid gene encoding additional polypeptide sequence such as a nucleic acid encoding a chimeric polypeptide, e.g., one encoding an antibody fragment linked to a cytotoxic polypeptide. Alternatively, HAAH expression is inhibited by administering a ribozyme or a compound which inhibits binding of Fos or Jun to an HAAH promoter sequence.

[0010] Compounds, which inhibit an enzymatic activity of HAAH, are useful to inhibit tumor growth in a mammal. By enzymatic activity of HAAH is meant hydroxylation of an epidermal growth factor (EGF)-like domain of a polypeptide. For example an EGF-like domain has the consensus sequence CX₇CX₄CX₁₀CXCX₈C (SEQ ID NO:1). HAAH hydroxylase activity is inhibited intracellularly. For example, a dominant negative mutant of HAAH (or a nucleic acid encoding such a mutant) is administered. The dominant negative HAAH mutant contains a mutation which changes a ferrous iron binding site from histidine of a naturally-occurring HAAH sequence to a non-iron-binding amino acid, thereby abolishing the hydroxylase activity of HAAH. The histidine to be mutated, e.g., deleted or substituted, is located in the carboxyterminal catalytic domain of HAAH. For example, the mutation is located between amino acids 650-700 (such as the His motif, underlined sequence of SEQ ID NO:2) the native HAAH sequence. For example, the mutation is at residues 671, 675, 679, or 690 of SEQ ID NO:2. An HAAH-specific intrabody is also useful to bind to

[0011] For example, a compound which inhibits HAAH hydroxylation is a polypeptide that binds a HAAH ligand but does not transduce an intracellular signal or an polypeptide which contains a mutation in the catalytic site of HAAH. Such a polypeptide contains an amino acid sequence that is at least 50% identical to a naturally-occurring HAAH amino acid sequence or a fragment thereof and which has the ability to inhibit HAAH hydroxylation of substrates containing an EGF-like repeat sequence. More preferably, the polypeptide contains an amino acid sequence that is at least 75%, more preferably at least 85%, more preferably at least 95% identical to SEQ ID NO: .

[0012] A substantially pure HAAH polypeptide or HAAH-derived polypeptide such as a mutated HAAH polypeptide is preferably obtained by expression of a recombinant nucleic acid encoding the polypeptide or by chemically synthesizing the protein. A polypeptide or protein is substantially pure when it is separated from those contaminants which accompany it in its natural state (proteins and other naturally-occurring organic molecules). Typically, the polypeptide is substantially pure when it constitutes at least 60%, by weight, of the protein in the preparation. Preferably, the protein in the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, HAAH. Purity is measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. Accordingly, substantially pure polypeptides include recombinant polypeptides

derived from a eucaryote but produced in *E. coli* or another procaryote, or in a eucaryote other than that from which the polypeptide was originally derived.

[0013] Nucleic acid molecules which encode such HAAH or HAAH-derived polypeptides are also within the invention.

TABLE 2

HAAH cDNA sequence	
cggaccgtgc aatggcccag cgtaagaatg ccaagagcag cggcaacagc agcagcagcg	61
gctccggcag cggtagcacg agtgccggga gcagcagccc cggggcccgg agagagacaa	121
agcatggagg acacaagaat gggaggaaag gcggactctc gggaacttca ttcttcacgt	181
ggtttatggt gattgcattg ctgggcgtct ggacatctgt agctgtcgtt tggtttgatc	241
ttgttgacta tgaggaaagt ctaggaaaac taggaatcta tgatgctgat ggtgatggag	301
attttgatgt ggatgatgcc aaagttttac taggacttaa agagagatct acttcagagc	361
cagcagtcgc gccagaagag gctgagccac acactgagcc cgaggagcag gttcctgtgg	421
aggcagaacc ccagaatata gaagatgaag caaaagaaca aattcagtc cttctccatg	481
aaatggtaca cgcagaacat gttgagggag aagacttgca acaagaagat ggaccacacg	541
gagaaccaca acaagaggat gatgagtctt ttatggcgac tgatgtagat gatagatttg	601
agaccctgga acctgaagta tctcatgaag aaaccgagca tagttaccac gtggaagaga	661
cagtttcaca agactgtaat caggatatgg aagagatgat gtctgagcag gaaaatccag	721
attccagtga accagtagta gaagatgaaa gattgcacca tgatacagat gatgtaacat	781
accaagtcta tgaggacaa gcagtatatg aacctctaga aaatgaaggg atagaaatca	841
cagaagtaac tgctccccct gaggataatc ctgtagaaga ttcacaggta attgtagaag	901
aagtaagcat ttttctctgt gaagaacagc aggaagtacc accagaaca aatagaaaaa	961
cagatgatcc agaacaaaa gcaaaagtta agaaaagaa gcctaaactt ttaataaat	1021
ttgataagac tattaagct gaacttgatg ctgcagaaaa actccgtaaa aggggaaaaa	1081
ttgaggaagc agtgaatgca tttaaagaac tagtacgcaa ataccctcag agtccacgag	1141
caagatatgg gaaggcgag tgtgaggatg atttggtgta gaaggaggaga agtaatgagg	1201
tgctacgtgg agccatcgag acctaccaag aggtggccag cctacctgat gtccctgcag	1261
acctgctgaa gctgagtgtt aagcgtcgtc cagacaggca acaatttcta ggtcatatga	1321
gaggttccct gcttaccctg cagagattag ttcaactatt tcccaatgat acttccttaa	1381
aaaatgacct tggcgtggga tacctcttga taggagataa tgacaatgca aagaaagttt	1441
atgaagaggt gctgagtgtg acacctaag atggctttgc taaagtccat tatggcttca	1501
tcctgaaggc acagaacaaa attgctgaga gcacccata tttaaaggaa ggaatagaat	1561
ccggagatcc tggcactgat gatgggagat tttatttcca cctgggggat gccatgcaga	1621
gggttggaag caaagaggca tataagtgg atgagcttgg gcacaagaga ggacactttg	1681
catctgtctg gcaacgctca ctctacaatg tgaatggact gaaagcacag ccttggtgga	1741
ccccaaaaga aacgggctac acagagttag taaagtcttt agaaagaaac tgaagttaa	1801
tccgagatga aggccttgca gtgatggata aagccaaagg tctcttcctg cctgaggatg	1861
aaaacctgag ggaagaaagg gactggagcc agttcacgct gtggcagcaa ggaagaagaa	1921
atgaaaatgc ctgcaaaagg gctcctaaaa cctgtacctt actagaaaag ttccccgaga	1981
caacaggatg cagaagagga cagatcaaat attccatcat gcaccccgag actcacgtgt	2041
ggccgcacac agggcccaca aactgcaggc tccgaatgca cctgggcttg gtgattccca	2101

TABLE 2-continued

HAAH cDNA sequence	
aggaaggctg caagattcga tgtgccaacg agaccaggac ctgggaggaa ggcaagggtgc	2161
tcatctttga tgactccttt gagcacgagg tatggcagga tgctcatctt ttccggctga	2221
tattcatcgt ggatgtgtgg catccggaac tgacaccaca gcagagacgc agccttccag	2281
caatttagca tgaattcatg caagcttggg aaactctgga gaga	

(SEQ ID NO:3 ; GENBANK Accession No. S83325; codon encoding initiating methionine is underlined).

[0014] Methods of inhibiting tumor growth also include administering a compound which inhibits HAAH hydroxylation of a NOTCH polypeptide. For example, the compound inhibits hydroxylation of an EGF-like cysteine-rich repeat sequence in a NOTCH polypeptide, e.g., one containing the consensus sequence CDXXXCXXKXGNXG-CDXXCNNAACXXDGXDC (SEQ ID NO:4). Polypeptides containing an EGF-like cysteine-rich repeat sequence are administered to block hydroxylation of endogenous NOTCH.

[0015] Growth of a tumor which overexpresses HAAH is also inhibited by administering a compound which inhibits signal transduction through the insulin receptor substrate (IRS) signal transduction pathway. Preferably the compound inhibits IRS phosphorylation. For example, the compound is a peptide or non-peptide compound which binds to and inhibits phosphorylation at residues 46, 465, 551, 612, 632, 662, 732, 941, 989, or 1012 of SEQ ID NO:5. Compounds include polypeptides such those which block an IRS phosphorylation site such as a Glu/Tyr site. Antibodies such as those which bind to a carboxyterminal domain of IRS containing a phosphorylation site block IRS phosphorylation, and as a consequence, signal transduction along the pathway. Inhibition of IRS phosphorylation in turn leads to inhibition of cell proliferation. Other compounds which inhibit IRS phosphorylation include vitamin D analogue EB1089 and Wortmannin.

[0016] HAAH-overproducing tumor cells were shown to express HAAH both intracellularly and on the surface of the tumor cell. Accordingly, a method of killing a tumor cell is carried out by contacting such a tumor cell with a cytotoxic agent linked to an HAAH-specific antibody. The HAAH-specific antibody (antibody fragment, or ligand which binds to extracellular HAAH) directs the chimeric polypeptide to the surface of the tumor cell allowing the cytotoxic agent to damage or kill the tumor cell to which the antibody is bound. The monoclonal antibody binds to an epitope of HAAH such as an epitope exposed on the surface of the cell or in the catalytic site of HAAH. The cytotoxic composition preferentially kills tumor cells compared to non-tumor cell.

[0017] Screening methods to identify anti-tumor agents which inhibit the growth of tumors which overexpress HAAH are also within the invention. A screening method used to determine whether a candidate compound inhibits HAAH enzymatic activity includes the following steps: (a) providing a HAAH polypeptide, e.g., a polypeptide which contains the carboxyterminal catalytic site of HAAH; (b) providing a polypeptide comprising an EGF-like domain; (c)

contacting the HAAH polypeptide or the EGF-like polypeptide with the candidate compound; and (d) determining hydroxylation of the EGF-like polypeptide of step (b). A decrease in hydroxylation in the presence of the candidate compound compared to that in the absence of said compound indicates that the compound inhibits HAAH hydroxylation of EGF-like domains in proteins such as NOTCH.

[0018] Anti-tumor agents which inhibit HAAH activation of NOTCH are identified by (a) providing a cell expressing HAAH; (b) contacting the cell with a candidate compound; and (c) measuring translocation of activated NOTCH to the nucleus of said cell. Translocation is measured by using a reagent such as an antibody which binds to a 110 kDa activation fragment of NOTCH. A decrease in translocation in the presence of the candidate compound compared to that in the absence of the compound indicates that the compound inhibits HAAH activation of NOTCH, thereby inhibiting NOTCH-mediated signal transduction and proliferation of HAAH-overexpressing tumor cells.

[0019] Nucleotide and amino acid comparisons described herein were carried out using the Lasergene software package (DNASTAR, Inc., Madison, Wis.). The MegAlign module used was the Clustal V method (Higgins et al., 1989, CABIOS 5(2):151-153). The parameter used were gap penalty 10, gap length penalty 10.

[0020] Hybridization is carried out using standard techniques, such as those described in Ausubel et al. (*Current Protocols in Molecular Biology*, John Wiley & Sons, 1989). "High stringency" refers to nucleic acid hybridization and wash conditions characterized by high temperature and low salt concentration, e.g., wash conditions of 65° C. at a salt concentration of 0.1× SSC. "Low" to "moderate" stringency refers to DNA hybridization and wash conditions characterized by low temperature and high salt concentration, e.g., wash conditions of less than 60° C. at a salt concentration of at least 1.0× SSC. For example, high stringency conditions include hybridization at 42° C. in the presence of 50% formamide; a first wash at 65° C. in the presence of 2× SSC and 1% SDS; followed by a second wash at 65° C. in the presence of 0.1× SSC. Lower stringency conditions suitable for detecting DNA sequences having about 50% sequence identity to an HAAH gene sequence are detected by, for example, hybridization at about 42° C. in the absence of formamide; a first wash at 42° C., 6× SSC, and 1% SDS; and a second wash at 50° C., 6× SSC, and 1% SDS.

[0021] Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] **FIG. 1** is a bar graph showing colony formation induced by transient transfection of NIH-3T3 cells with various AAH cDNAs. Colony formation was induced by transient transfection with 10 μ g DNA. In contrast, the mutant murine AAH construct without enzymatic activity has no transforming activity. The data is presented as mean number of transformed foci \pm SEM.

[0023] **FIG. 2** is a bar graph showing the results of a densitometric analysis of a Western blot assay of proteins produced by various murine AAH stably transfected cell clones. In clones 7 and 18, there was a modest increase in HAAH gene expression, while the overexpression was to a lesser degree in clone 16.

[0024] **FIGS. 3A-B** are bar graphs showing colony formation in soft agar exhibited by HAAH stably transfected clones compared to HAAH enzymatic activity.

[0025] **FIG. 3A** shows a measurement of murine AAH enzymatic activity in clones 7, 16 and 18, and

[0026] **FIG. 3B** shows colony formation exhibited by clones 7, 16 and 18. Data is presented as mean number of colonies 10 days after plating \pm SEM. All three clones with modest increases in HAAH enzymatic activity, that correlated with protein expression, exhibited anchorage independent growth.

[0027] **FIG. 4** is a bar graph showing tumor formation in nude mice injected with transfected clones overexpressing murine AAH. Tumor growth was assessed after 30 days. Mean tumor weight observed in mice injected with clones 7, 16 and 18 as compared to mock DNA transfected clone. All animals injected with clones overexpressing HAAH developed tumors.

[0028] **FIGS. 5A-D** are bar graphs showing increased AAH expression in PNET2 (**FIGS. 5A, 5C**) and SH-Sy5y (**FIG. 5B**) cells treated with retinoic acid (**FIGS. 5A, 5B**) or phorbol ester myristate (PMA; **FIG. 5C**) to induce neurite outgrowth as occurs during tumor cell invasion. The cells were treated with 10 μ M retinoic acid or 100 nM PMA for 0, 1, 2, 3, 4, or 7 days. Cell lysates were analyzed by Western blot analysis using a HAAH-specific monoclonal antibody to detect the 85 kDa AAH protein. The levels of immunoreactivity were measured by volume densitometry (arbitrary units). The graphs indicate the mean \pm S.D. of results obtained from three separate experiments. In **FIG. 5D**, PNET2 cells were treated for 24 hours with sub-lethal concentrations of H₂O₂ to induce neurite retraction. Viability of greater than 90% of the cells was demonstrated by Trypan blue dye exclusion. Similar results were obtained for SH-Sy5y cells.

[0029] **FIG. 6** is a bar graph showing the effects of AAH over-expression on the levels of anti-apoptosis (Bcl-2), cell cycle-mitotic inhibitor (p16 and p21/Waf1), and proliferation (proliferating cell nuclear antigen; PCNA) molecules. PNET2 neuronal cells were stably transfected with the full-length human cDNA encoding AAH (HAAH) or empty vector (pcDNA). AAH gene expression was under control of a CMV promoter. Western blot analysis was performed with cell lysates prepared from cultures that were 70 to 80 percent confluent. Protein loading was equivalent in each lane. Replicate blots were probed with the different

antibodies. Bar graphs depict the mean S.D.'s of protein expression levels measured in three experiments. All differences are statistically significant by Student T-test analysis ($P < 0.01$ – $P < 0.001$).

[0030] **FIG. 7** is a diagram of showing the components of the IRS-1 signal transduction pathway.

[0031] **FIG. 8** is a line graph showing growth curves generated in cells expressing the antisense HAAH compared to controls expressing GFP.

[0032] **FIG. 9** is a diagram of the functional domains of the hIRS-1 protein and structural organization of the point mutants. All mutant and "wild type" hIRS-1 proteins construct contain a FLAG (F) epitope (DYKDDDDK; SEQ ID NO:7) at the C-terminus. PH and PTB indicate pleckstrin homology and phosphotyrosine binding, regions, respectively.

DETAILED DESCRIPTION

[0033] HAAH is a protein belonging to the (α -ketoglutarate dependent dioxygenase family of prolyl and lysyl hydroxylases which play a key role in collagen biosynthesis. This molecule hydroxylates aspartic acid or asparagine residues in EGF-like domains of several proteins in the presence of ferrous iron. These EGF-like domains contain conserved motifs, that form repetitive sequences in proteins such as clotting factors, extracellular matrix proteins, LDL receptor, NOTCH homologues or NOTCH ligand homologues.

[0034] The α -ketoglutarate-dependent dioxygenase aspartyl (asparaginyl) beta-hydroxylase (AAH) specifically hydroxylates one aspartic or asparagine residue in EGF-like domains of various proteins. The 4.3-kb cDNA encoding the human AspH (hAspH) hybridizes with 2.6 kb and 4.3 kb transcripts in transformed cells, and the deduced amino acid sequence of the larger transcript encodes an protein of about 85 kDa. Both in vitro transcription and translation and Western blot analysis also demonstrate a 56-kDa protein that may result from post-translational cleavage of the catalytic C terminus.

[0035] An physiological function of AAH is the post-translational beta-hydroxylation of aspartic acid in vitamin K-dependent coagulation proteins. However, the abundant expression of AAH in several malignant neoplasms, and low levels of AAH in many normal cells indicate a role for this enzyme in malignancy. The AAH gene is also highly expressed in cytotrophoblasts, but not syncytiotrophoblasts of the placenta. Cytotrophoblasts are invasive cells that mediate placental implantation. The increased levels of AAH expression in human cholangiocarcinomas, hepatocellular carcinomas, colon cancers, and breast carcinomas were primarily associated with invasive or metastatic lesions. Moreover, overexpression of AAH does not strictly reflect increased DNA synthesis and cellular proliferation since high levels of AAH immunoreactivity were observed in 100 percent of cholangiocarcinomas, but not in human or experimental disease processes associated with regeneration or nonneoplastic proliferation of bile ducts. AAH overexpression and attendant high levels of beta hydroxylase activity lead to invasive growth of transformed neoplastic cells. Detection of an increase in HAAH expression is useful for early and reliable diagnosis of the cancer types which have now been characterized as overexpressing this gene product.

[0036] Diagnosis of Malignant Tumors

[0037] HAAH is overexpressed in many tumors of endodermal origin and in at least 95% of CNS tumors compared to normal noncancerous cells. An increase in HAAH gene product in a patient-derived tissue sample (e.g., solid tissue or bodily fluid) is carried out using standard methods, e.g., by Western blot assays or a quantitative assay such as ELISA. For example, a standard competitive ELISA format using an HAAH-specific antibody is used to quantify patient HAAH levels. Alternatively, a sandwich ELISA using a first antibody as the capture antibody and a second HAAH-specific antibody as a detection antibody is used.

[0038] Methods of detecting HAAH include contacting a component of a bodily fluid with an HAAH-specific antibody bound to solid matrix, e.g., microtiter plate, bead, dipstick. For example, the solid matrix is dipped into a patient-derived sample of a bodily fluid, washed, and the solid matrix is contacted with a reagent to detect the presence of immune complexes present on the solid matrix.

[0039] Proteins in a test sample are immobilized on (bound to) a solid matrix. Methods and means for covalently or noncovalently binding proteins to solid matrices are known in the art. The nature of the solid surface may vary depending upon the assay format. For assays carried out in microtiter wells, the solid surface is the wall of the well or cup. For assays using beads, the solid surface is the surface of the bead. In assays using a dipstick (i.e., a solid body made from a porous or fibrous material such as fabric or paper) the surface is the surface of the material from which the dipstick is made. Examples of useful solid supports include nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidene fluoride (known as IMMULON™), diazotized paper, nylon membranes, activated beads, and Protein A beads. The solid support containing the antibody is typically washed after contacting it with the test sample, and prior to detection of bound immune complexes. Incubation of the antibody with the test sample is followed by detection of immune complexes by a detectable label. For example, the label is enzymatic, fluorescent, chemiluminescent, radioactive, or a dye. Assays which amplify the signals from the immune complex are also known in the art, e.g., assays which utilize biotin and avidin.

[0040] An HAAH-detection reagent, e.g., an antibody, is packaged in the form of a kit, which contains one or more HAAH-specific antibodies, control formulations (positive and/or negative), and/or a detectable label. The assay may be in the form of a standard two-antibody sandwich assay format known in the art.

[0041] Production of HAAH-specific Antibodies

[0042] Anti-HAAH antibodies were obtained by techniques well known in the art. Such antibodies are polyclonal or monoclonal. Polyclonal antibodies were obtained, for example, by the methods described in Ghose et al., *Methods in Enzymology*, Vol. 93, 326-327, 1983. An HAAH polypeptide, or an antigenic fragment thereof, was used as the immunogen to stimulate the production of polyclonal antibodies in the antisera of rabbits, goats, sheep, or rodents. Antigenic polypeptides for production of both polyclonal and monoclonal antibodies useful as immunogens include

polypeptides which contain an HAAH catalytic domain. For example, the immunogenic polypeptide is the full-length mature HAAH protein or an HAAH fragment containing the carboxyterminal catalytic domain e.g., an HAAH polypeptide containing the His motif of SEQ ID NO:2.

[0043] Antibodies which bind to the same epitopes as those antibodies disclosed herein as identified using standard methods, e.g., competitive binding assays, known in the art.

[0044] Monoclonal antibodies were obtained by standard techniques. Ten μ g of purified recombinant HAAH polypeptide was administered to mice intraperitoneally in complete Freund's adjuvant, followed by a single boost intravenously (into the tail vein) 3-5 months after the initial inoculation. Antibody-producing hybridomas were made using standard methods. To identify those hybridomas producing antibodies that are highly specific for an HAAH polypeptide, hybridomas were screened using the same polypeptide immunogen used to immunize. Those antibodies which were identified as having HAAH-binding activity are also screened for the ability to inhibit HAAH catalytic activity using the enzymatic assays described below. Preferably, the antibody has a binding affinity of at least about 10^8 liters/mole and more preferably, an affinity of at least about 10^9 liters/mole.

[0045] Monoclonal antibodies are humanized by methods known in the art, e.g. MAbs with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, Calif.).

[0046] HAAH-specific intrabodies are produced as follows. Following identification of a hybridoma producing a suitable monoclonal antibody, DNA encoding the antibody is cloned. DNA encoding a single chain HAAH-specific antibody in which heavy and light chain variable domains are separated by a flexible linker peptide is cloned into an expression vector using known methods (e.g., Marasco et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:7889-7893 and Marasco et al., 1997, *Gene Therapy* 4:11-15). Such constructs are introduced into cells, e.g., using standard gene delivery techniques for intracellular production of the antibodies. Intracellular antibodies, i.e., intrabodies, are used to inhibit signal transduction by HAAH. Intrabodies which bind to a carboxyterminal catalytic domain of HAAH inhibit the ability of HAAH to hydroxylate EGF-like target sequences.

[0047] Methods of linking HAAH-specific antibodies (or fragments thereof) which bind to cell surface exposed epitopes of HAAH on the surface of a tumor cell are linked to known cytotoxic agents, e.g. ricin or diphtheria toxin, using known methods.

[0048] Methods of Treating Malignant Tumors

[0049] Patients with tumors characterized as overexpressing HAAH as such tumors of endodermal origin or CNS tumors are treated by administering HAAH antisense nucleic acids.

[0050] Antisense therapy is used to inhibit expression of HAAH in patients suffering from hepatocellular carcinomas,

cholangiocarcinomas, glioblastomas and neuroblastomas. For example, an HAAH antisense strand (either RNA or DNA) is directly introduced into the cells in a form that is capable of binding to the mRNA transcripts. Alternatively, a vector containing a sequence which, once within the target cells, is transcribed into the appropriate antisense mRNA, may be administered. Antisense nucleic acids which hybridize to target mRNA decrease or inhibit production of the polypeptide product encoded by a gene by associating with the normally single-stranded mRNA transcript, thereby interfering with translation and thus, expression of the protein. For example, DNA containing a promoter, e.g., a tissue-specific or tumor specific promoter, is operably linked to a DNA sequence (an antisense template), which is transcribed into an antisense RNA. By "operably linked" is meant that a coding sequence and a regulatory sequence(s) (i.e., a promoter) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

[0051] Oligonucleotides complementary to various portions of HAAH mRNA are tested in vitro for their ability to decrease production of HAAH in tumor cells (e.g., using the FOCUS hepatocellular carcinoma (HCC) cell line) according to standard methods. A reduction in HAAH gene product in cells contacted with the candidate antisense composition compared to cells cultured in the absence of the candidate composition is detected using HAAH-specific antibodies or other detection strategies. Sequences which decrease production of HAAH in in vitro cell-based or cell-free assays are then be tested in vivo in rats or mice to confirm decreased HAAH production in animals with malignant neoplasms.

[0052] Antisense therapy is carried out by administering to a patient an antisense nucleic acid by standard vectors and/or gene delivery systems. Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses and adeno-associated viruses, among others. A reduction in HAAH production results in a decrease in signal transduction via the IRS signal transduction pathway. A therapeutic nucleic acid composition is formulated in a pharmaceutically acceptable carrier. The therapeutic composition may also include a gene delivery system as described above. Pharmaceutically acceptable carriers are biologically compatible vehicles which are suitable for administration to an animal: e.g., physiological saline. A therapeutically effective amount of a compound is an amount which is capable of producing a medically desirable result such as reduced production of an HAAH gene product or a reduction in tumor growth in a treated animal.

[0053] Parenteral administration, such as intravenous, subcutaneous, intramuscular, and intraperitoneal delivery routes, may be used to deliver nucleic acids or HAAH-inhibitory peptides or non-peptide compounds. For treatment of CNS tumors, direct infusion into cerebrospinal fluid is useful. The blood-brain barrier may be compromised in cancer patients, allowing systemically administered drugs to pass through the barrier into the CNS. Liposome formulations of therapeutic compounds may also facilitate passage across the blood-brain barrier.

[0054] Dosages for any one patient depends upon many factors, including the patient's size, body surface area, age,

the particular nucleic acid to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Dosage for intravenous administration of nucleic acids is from approximately 10^6 to 10^{22} copies of the nucleic acid molecule.

[0055] Ribozyme therapy is also be used to inhibit HAAH gene expression in cancer patients. Ribozymes bind to specific mRNA and then cut it at a predetermined cleavage point, thereby destroying the transcript. These RNA molecules are used to inhibit expression of the HAAH gene according to methods known in the art (Sullivan et al., 1994, *J. Invest. Derm.* 103:85S-89S; Czubayko et al., 1994, *J. Biol. Chem.* 269:21358-21363; Mahieu et al, 1994, *Blood* 84:3758-65; Kobayashi et al. 1994, *Cancer Res.* 54:1271-1275).

[0056] Methods of Identifying Compounds that Inhibit HAAH Enzymatic Activity

[0057] Aspartyl (asparaginyl) beta-hydroxylase activity (AAH) is measured in vitro or in vivo. For example, HAAH catalyzes post-translational modification of β carbon of aspartyl and asparaginyl residues of EGF-like polypeptide domains. An assay to identify compounds which inhibit hydroxylase activity is carried out by comparing the level of hydroxylation in an enzymatic reaction in which the candidate compound is present compared to a parallel reaction in the absence of the compound (or a predetermined control value). Standard hydroxylase assays carried out in a testtube are known in the art, e.g., Lavaisiere et al., 1996, *J. Clin. Invest.* 98:1313-1323; Jia et al., 1992, *J. Biol. Chem.* 267:14322-14327; Wang et al., 1991, *J. Biol. Chem.* 266:14004-14010; or Gronke et al., 1990, *J. Biol. Chem.* 265:8558-8565. Hydroxylase activity is also measured using carbon dioxide ($^{14}\text{CO}_2$ capture assay) in a 96-well microtiter plate format (Zhang et al., 1999, *Anal. Biochem.* 271:137-142. These assays are readily automated and suitable for high throughput screening of candidate compounds to identify those with hydroxylase inhibitory activity.

[0058] Candidate compound which inhibit HAAH activation of NOTCH are identified by detecting a reduction in activated NOTCH in a cell which expresses or overexpresses HAAH, e.g., FOCUS HCC cells. The cells are cultured in the presence of a candidate compound. Parallel cultures are incubated in the absence of the candidate compound. To evaluate whether the compound inhibits HAAH activation of NOTCH, translocation of activated NOTCH to the nucleus of the cell is measured. Translocation is measured by detecting a 110 kDa activation fragment of NOTCH in the nucleus of the cell. The activation fragment is cleaved from the large (approximately 300 kDa) transmembrane NOTCH protein upon activation. Methods of measuring NOTCH translocation are known, e.g. those described by Song et al., 1999, *Proc. Natl. Acad. Sci. U.S.A.* 96:6959-6963 or Capobianco et al., 1997, *Mol. Cell Biol.* 17:6265-6273. A decrease in translocation in the presence of the candidate compound compared to that in the absence of the compound indicates that the compound inhibits HAAH activation of NOTCH, thereby inhibiting NOTCH-mediated signal transduction and proliferation of HAAH-overexpressing tumor cells.

[0059] Methods of screening for compounds which inhibit phosphorylation of IRS are carried out by incubating IRS-

expressing cells in the presence and absence of a candidate compound and evaluating the level of IRS phosphorylation in the cells. A decrease in phosphorylation in cells cultured in the presence of the compound compared to in the absence of the compound indicates that the compound inhibits IRS-1 phosphorylation, and as a result, growth of HAAH-overexpressing tumors. Alternatively, such compounds are identified in an *in vitro* phosphorylation assay known in the art, e.g., one which measured phosphorylation of a synthetic substrate such as poly (Glu/Tyr).

EXAMPLE 1

Increased Expression of HAAH is Associated with Malignant Transformation

[0060] HAAH is a highly conserved enzyme that hydroxylates EGF-like domains in transformation associated proteins. The HAAH gene is overexpressed in human hepatocellular carcinomas and cholangiocarcinomas. HAAH gene expression was found to be undetectable during bile duct proliferation in both human disease and rat models compared to cholangiocarcinoma. Overexpression of HAAH in NIH-3T3 cells was associated with generation of a malignant phenotype, and enzymatic activity was found to be required for cellular transformation. The data described below indicate that overexpression of HAAH is linked to cellular transformation of biliary epithelial cells.

[0061] To identify molecules that are specifically overexpressed in transformed malignant cells of human hepatocyte origin, the FOCUS hepatocellular carcinoma (HCC) cell line was used as an immunogen to generate monoclonal antibodies (mAb) that specifically or preferentially recognize proteins associated with the malignant phenotype. A lambda GT11 cDNA expression library derived from HepG2 HCC cells was screened, and HAAH-specific mAb produced against the FOCUS cell line was found to recognize an epitope on a protein encoded by an HAAH cDNA. The HAAH enzyme was found to be upregulated in several different human transformed cell lines and tumor tissues compared to adjacent human tissue counterparts. The overexpressed HAAH enzyme in different human malignant tissues was found to be catalytically active.

[0062] HAAH gene expression was examined in proliferating bile ducts and in NIH 3T3 cells. Its role in the generation of the malignant phenotype was measured by the formation of transformed foci, growth in soft agar as an index of anchorage independent growth and tumor formation in nude mice. The role of enzymatic activity in the induction of transformed phenotype was measured by using a cDNA construct with a mutation in the catalytic site that abolished hydroxylase activity. The results indicated that an increase in expression of HAAH gene is associated with malignant transformation of bile ducts.

[0063] The following materials and methods were used to generate the data described below.

[0064] Antibodies

[0065] The FB50 monoclonal antibody was generated by cellular immunization of Balb/C mice with FOCUS HCC cells. A monoclonal anti-Dengue virus antibody was used as a non-relevant control. The HBOH2 monoclonal antibody was generated against a 52 kDa recombinant HAAH

polypeptide and recognizes the catalytic domain of beta-hydroxylase from mouse and human proteins. Polyclonal anti-HAAH antibodies cross-react with rat hydroxylase protein. Control antibody anti-Erk-1 was purchased from Santa Cruz Biotechnology, Inc, CA. Sheep anti-mouse and donkey anti-rabbit antisera labeled with horseradish peroxidase were obtained from Amersham, Arlington Heights, Ill.

[0066] Constructs

[0067] The murine full length AAH construct (pNH376) and the site-directed mutation construct (pNH376-H660) with abolished catalytic activity were cloned into the eukaryotic expression vector pcDNA3 (Invitrogen Corp., San Diego, Calif.). The full length human AAH was cloned into prokaryotic expression vector pBC-SK+ (Stratagene, La Jolla, Calif.). The full length human AAH (GENBANK Accession No. S83325) was subcloned into the EcoRI site of the pcDNA3 vector.

[0068] Animal Model of Bile Duct Proliferation

[0069] Rats were divided into 9 separate groups of 3 animals each except for group 9 which contained 5 rats. Group 1 was the non-surgical control group, and group 2 was the sham-operated surgical control. The remaining groups underwent common bile duct ligation to induce intrahepatic bile duct proliferation and were evaluated at 6, 12, 24, 48 hours and 4, 8 and 16 days as shown in Table 3. Animals were asphyxiated with CO₂, and liver samples were taken from left lateral and median lobes, fixed in 2% paraformaldehyde and embedded in paraffin. Liver samples (5 μ m) were cut and stained with hematoxylin and eosin to evaluate intrahepatic bile duct proliferation. Immunohistochemistry was performed with polyclonal anti-HAAH antibodies that cross-react with the rat protein to determine levels of protein expression.

[0070] Bile Duct Proliferation Associated with Primary Sclerosing Cholangitis (PSC)

[0071] Liver biopsy samples were obtained from 7 individuals with PSC and associated bile duct proliferation. These individuals were evaluated according to standard gastroenterohepatological protocols. Patients were 22-46 years of age and consisted of 4 males and 3 females. Four had associated inflammatory bowel disease (3 ulcerative colitis and 1 Crohn's colitis). All patients underwent a radiological evaluation including abdominal ultrasonography and endoscopic retrograde cholangiopancreatography to exclude the diagnosis of extrahepatic biliary obstruction. Tissue sections were prepared from paraffin embedded blocks and were evaluated by hematoxylin and eosin staining for bile duct proliferation. Expression of HAAH was determined by immunohistochemistry using an HAAH-specific monoclonal antibody such as FB50.

[0072] Immunohistochemistry

[0073] Liver tissue sections (5 μ m) were deparaffinized in xylene and rehydrated in graded alcohol. Endogenous peroxidase activity was quenched by a 30-minute treatment with 0.6% H₂O₂ in 60% methanol. Endogenous biotin was masked by incubation with avidin-biotin blocking solutions (Vector Laboratories, Burlingame, Calif.). The FB50 mAb (for PSC samples) and polyclonal anti-HAAH-hydroxylase antibodies (for rat liver samples) were added to slides in a humidified chamber at 4° C. overnight. Immunohistochemi-

cal staining was performed using a standard avidin-biotin horseradish peroxidase complex (ABC) method using Vectastain Kits with diaminobenzidine (DAB) as the chromogen according to manufacturer's instructions (Vector Laboratories, Inc., Burlingame, Calif.). Tissue sections were counterstained with hematoxylin, followed by dehydration in ethanol. Sections were examined by a light microscopy for bile duct proliferation and HAAH protein expression. Paraffin sections of cholangiocarcinoma and placenta were used as positive controls, and hepatosteatoses samples were used as a negative controls. To control for antibody binding specificity, adjacent sections were immunostained in the absence of a primary antibody, or using non-relevant antibody to Dengue virus. As a positive control for tissue immunoreactivity, adjacent sections of all specimens were immunostained with monoclonal antibody to glyceraldehyde 3-phosphate dehydrogenase.

[0074] Western Blot Analysis

[0075] Cell lysates were prepared in a standard radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors. The total amount of protein in the lysates was determined by Bio-Rad calorimetric assay (Bio Rad, Hercules, Calif.) followed by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to PVDF membranes, and subjected to Western blot analysis using FB50, HBOH2, anti-Erk-1 (used as an internal control for protein loading) as primary, sheep anti-mouse and donkey anti-rabbit antisera labeled with horseradish peroxidase as secondary antibodies. Antibody binding was detected with enhanced chemiluminescence reagents (SuperSignal, Pierce Chemical Company, Rockford, Ill.) and film autoradiography. The levels of immunoreactivity were measured by volume densitometry using NIH Image software.

[0076] Enzymatic Activity Assay

[0077] AAH activity was measured in cell lysates using the first EGF-like domain of bovine protein S as substrate where ^{14}C -labeled α -ketoglutarate hydroxylates the domain releasing ^{14}C containing CO_2 according to standard methods, e.g., those described by Jia et al., 1992, J. Biol. Chem. 267:14322-14327; Wang et al., 1991, J. Biol. Chem. 266:14004-14010; or Gronke et al., 1990, J. Biol. Chem. 265:8558-8565. Incubations were carried out at 37°C . for 30 min in a final volume of 40 μl containing 48 μg of crude cell extract protein and 75 μM EGF substrate.

[0078] Cell Transfection Studies

[0079] The NIH-3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Washington, D.C.) supplemented with 10% heat-inactivated fetal calf serum (FCS; Sigma Chemical Co., St. Louis, Mo.), 1% L-glutamine, 1% non-essential amino acids and 1% penicillin-streptomycin (GIBCO BRL, Life Technologies, Inc., Grand Island, N.Y.). Subconfluent NIH-3T3 cells (3×10^5 cells/60-mm dish) were transfected with 10 μg of one of the following plasmids: 1) non-recombinant pcDNA3 vector (Invitrogen Corp., San Diego, Calif.) as a negative control; 2) pNH376-H660, the murine AAH cDNA that was mutated in the catalytic domain and cloned into the pcDNA3 vector driven by a CMV promoter; 3) pNH376, the wild type murine AAH cDNA cloned into the pcDNA3 vector; 4) pCDHH, wild type human AAH cDNA cloned into the

pcDNA3 vector; or 5) pLNCX-UP1, a cDNA that encodes v-Src oncogene (positive control). Cells were transfected using the calcium phosphate transfection kit according to manufacturer's instructions (5 Prime-3 Prime, Inc., Boulder, Colo.). Comparison of cellular transfection efficiency was assessed with the various constructs. For this procedure, confluent plates obtained 48 hours after transfection were split and reseeded into 12 separate 6-cm dishes, and 6 of them were made to grow in the presence of 400 $\mu\text{g}/\text{ml}$ G-418 (GIBCO BRL, Life Technologies, Inc., Grand Island, N.Y.) containing medium. The number of G-418 resistant foci was determined at 14 days after transfection and used to correct for any variability in transfection efficiency.

[0080] Transformation Assay

[0081] The NIH-3T3 cells were transfected with the various constructs and allowed to reach confluence after 48 hours as described above. Each 6 cm dish was split and seeded into 12 different 6 cm dishes. While 6 of them were made to grow in the presence of G-418 to detect transfection efficiency, the other six were grown in complete medium without G-418 and with a medium change every 4th day. The number of transformed foci were counted in these plates without G-418 and expressed as transformed foci per μg transfected DNA.

[0082] Anchorage-independent Cell Growth Assay

[0083] A limiting dilution technique (0.15 cell/well of a flat bottom 96-well-plate) was performed on transfectants grown in G-418 in order to isolate cell clones with different levels of HAAH activity as measured by Western blot analysis and enzymatic assay of hydroxylase activity. Cloned cell lines (1.0×10^4 cells) were suspended in complete medium containing 0.4% low-melting agarose (Sea-Plaque GTG Agarose; FMC Bioproducts, Rockland, Me.) and laid over a bottom agar mixture consisting of complete medium with 0.53% low-melting agarose. Each clone was assayed in triplicate. The clones were seeded under these conditions and 10 days later the size (positive growth >0.1 mm in diameter) and number of foci were determined.

[0084] Tumorigenicity in Nude Mice

[0085] The same clones as assessed in the anchorage independent growth assay were injected into nude mice and observed for tumor formation. Tumorigenicity was evaluated using 10 animals in each of 4 groups (Charles River Labs., Wilmington, Mass.). Group 1 received 1×10^7 cells stably transfected with mock DNA, Group 2-4 received 1×10^6 cells of clones stably transfected with pNH376 and expressing various levels of murine HAAH protein. Nude mice were kept under pathogen-free conditions in a standard animal facility. Thirty days after tumor cell inoculation, the animals were sacrificed using isoflurane (Aerrane, Anaquest, N.J.) containing chambers and the tumors were carefully removed and weight determined.

[0086] Animal Model of Bile Duct Proliferation

[0087] Following ligation of the common bile duct, intrahepatic bile duct proliferation was evident at 48 hours. Tissue samples obtained 8 and 16 days following common bile duct ligation revealed extensive bile duct proliferation as shown in Table 3.

TABLE 3

Bile duct proliferation and HAAH expression at different intervals after common bile duct ligation			
Group	Surgical Procedure	Microscopy*	Immunohisto- chemistry
1	no surgery	normal	negative
2	sham surgery	normal	negative
3	6 hours post ligation	normal	negative
4	12 hours post ligation	normal	negative
5	24 hours post ligation	normal	negative
6	48 hours post ligation	minimal bile duct prolif.	negative
7	4 days post ligation	moderate bile duct prolif.	negative
8	8 days post ligation	extensive bile duct prolif.	negative
9	16 days post ligation	extensive bile duct prolif.	negative

*Investigation was performed under light microscopy following a hematoxylin and eosin staining.

[0088] Immunohistochemical staining failed to detect presence of HAAH in proliferating bile ducts at any time. Analysis of HAAH expression in bile ducts derived from sham surgical controls was also negative, while all samples exhibited positive immunoreactivity with control antibodies to glyceraldehyde 3-phosphate dehydrogenase. Thus, bile duct proliferation was not associated with increased HAAH expression in this standard animal model system.

[0089] HAAH Expression in PSC

[0090] The liver biopsy specimens from patients with PSC exhibited bile duct proliferation accompanied by periductal fibrosis and a mononuclear inflammatory cell infiltrate without evidence of dysplasia. Adjacent sections immunostained with the an HAAH-specific monoclonal antibody had no detectable HAAH immunoreactivity in proliferating bile ducts. In contrast, sections of cholangiocarcinoma that were immunostained simultaneously using the same antibody and detection reagents manifested intense levels of HAAH immunoreactivity in nearly all tumor cells, whereas adjacent sections of the cholangiocarcinomas exhibited a negative immunostaining reaction with monoclonal antibody to Dengue virus. These findings indicate that HAAH expression was associated with malignant transformation rather than non-cancerous cellular proliferation of intrahepatic bile ducts.

[0091] HAAH Associated Transformation of NIH-3T3 Cells

[0092] The transforming capability of the murine and human AAH genes, as well as the murine AAH mutant construct without enzymatic activity were compared to mock DNA (negative control) and v-Src transfected NIH-3T3 cells (positive control). The transforming capability of murine AAH was found to be 2-3 times that of vector DNA control as shown in **FIG. 1**. The transforming capacity of the human gene was greater than that observed with the murine AAH (32 ± 1.5 versus 13 ± 2.6 transformed foci, respectively). The murine and human AAH transfected cells formed large

foci, resembling those of v-Src transfected fibroblasts, compared to the occasional much smaller foci observed in cells transfected with vector DNA that displayed the contact inhibition of fibroblast cell lines. Parallel experiments performed using the mutant pNH376-H660 construct without enzymatic activity revealed no transforming activity. This finding indicates that the enzymatic activity of HAAH is required for the transforming activity exhibited by the HAAH gene.

[0093] Anchorage-independent Cell Growth Assay

[0094] After transient transfection with the murine AAH construct, several different transformed foci were isolated for dilutional cloning experiments to establish stable transfected cell clones with different levels of HAAH gene expression. Nine different cloned cell lines were selected for further study. The expression level of the HAAH protein was determined by Western blot analysis. Clones 7 and 18 had a modest increase in HAAH protein expression, yet formed large colonies in soft agar (**FIG. 2**). Protein loading was equivalent in all lanes as shown by immunoblotting of the same membranes with an anti-Erk-1 monoclonal antibody. The increased protein expression was associated with increased enzymatic activity as shown in **FIG. 3**. The capability of these clones to exhibit anchorage independent cell growth in soft agar is presented in **FIG. 3**. All 3 clones with increased HAAH gene expression demonstrated anchorage independent cell growth compared to the mock DNA transfected clone.

[0095] Tumor Formation in Nude Mice

[0096] The 3 clones with increased HAAH gene expression were evaluated for the ability to form tumors in nude mice. Tumor size in the mouse given clone 18 was compared to a mock DNA transfected clone. Clones 7, 16 and 18 were highly transformed in this assay and produced large tumors with a mean weight of 2.5, 0.9 and 1.5 grams, respectively (**FIG. 4**). These data indicate that overexpression of HAAH contributes to induction and maintenance of the malignant phenotype in vivo.

[0097] High Level HAAH Expression is Indicative of Malignancy

[0098] In order to determine if HAAH expression was associated with malignancy rather than increased cell turnover, two models of bile duct proliferation were studied. In the animal model, ligation of the common bile duct induced extensive intrahepatic bile duct proliferation, yet there was no evidence of HAAH gene expression under these experimental conditions as shown in Table 3. Similarly, HAAH gene expression was assessed in a human disease model associated with bile duct proliferation since PSC is an autoimmune liver disease associated with destruction as well as proliferation of the intra and extrahepatic bile ducts. PSC is premalignant disease, and a significant proportion of affected individuals will eventually develop cholangiocarcinoma. However, no evidence for increased HAAH gene expression in the presence of extensive bile duct proliferation.

[0099] Having established that HAAH protein levels were elevated in cholangiocarcinoma and not in normal or proliferating bile ducts, the role of HAAH in the generation of a malignant phenotype was studied. The HAAH gene was transfected into NIH-3T3 cells and cellular changes, e.g.,

increased formation of transformed foci, colony growth in soft agar and tumor formation in nude mice associated with malignant transformation, were evaluated. The full-length murine and human AAH genes were cloned into expression constructs and transiently transfected into NIH-3T3 cells. An increased number of transformed foci was detected in cells transfected both with the murine and human AAH genes as compared to mock DNA transfected controls. The increased number of transformed foci, after controlling for transfection efficiency, was not as high compared to v-Src gene transfected cells used as a positive control. The enzymatic activity of the HAAH gene was required for a malignant phenotype because a mutant construct which abolished the catalytic site had no transforming properties. Several stable transfectants and cloned NIH-3T3 cell lines with a modest increase in HAAH protein levels and enzymatic activity were established. Such cell lines were placed in soft agar to examine anchorage independent cell growth as another property of the malignant phenotype. All cell lines grew in soft agar compared to mock DNA transfected control, and there was a positive correlation between the cellular level of HAAH gene expression and the number and size of colonies formed. Three of these cloned cell lines formed tumors in nude mice. All three cell lines with increased HAAH expression were oncogenic as shown by the development of large tumors as another well-known characteristic of the transformed phenotype.

[0100] To determine whether cellular changes induced by overexpression of HAAH were related to the enzymatic function, a site-directed mutation was introduced into the gene that changed the ferrous iron binding site from histidine to lysine at 660th position of mouse HAAH thereby abolishing hydroxylase activity of the murine HAAH. A corresponding mutation in HAAH is used as a dominant negative mutant to inhibit HAAH hydroxylase activity. The pNH376-H660 construct had no transformation activity indicating cellular changes of the malignant phenotype induced by overexpression depends on the enzymatic activity of the protein.

[0101] Notch receptors and their ligands have several EGF-like domains in the N-terminal region that contain the putative consensus sequence for beta-hydroxylation. Notch ligands are important elements of the Notch signal transduction pathway and interaction of Notch with its ligands occurs by means of EGF-like domains of both molecules. Point mutations affecting aspartic acid or asparagine residues in EGF-like domains that are the targets for beta-hydroxylation by HAAH reduce calcium binding and protein-protein interactions involved in the activation of downstream signal transduction pathways. Overexpression of HAAH and Notch protein hydroxylation by HAAH contributes to malignancy. Tumor growth is inhibited by decreasing Notch protein hydroxylation by HAAH

[0102] The data presented herein is evidence that high-level HAAH expression is linked to malignant transformation. An increase in expression of the HAAH cDNA in NIH-3T3 cells induced a transformed phenotype manifested by increased numbers of transformed foci, anchorage-independent growth, and tumorigenesis in nude mice. In addition, intact HAAH-enzyme was found to be required for HAAH-associated transformation. Accordingly, inhibition of as little as 20% of endogenous HAAH enzymatic activity or expression confers a therapeutic benefit. For example,

clinical benefit is achieved by 50%-70% inhibition of HAAH expression or activity after administration of an HAAH inhibitory compound compared to the level associated with untreated cancer cell or a normal noncancerous cell.

[0103] HAAH is regulated at the level of transcription. Only modest increases in HAAH expression and enzyme activity were required for cellular transformation. These results indicate that increased HAAH gene expression and enzyme activity contribute to the generation or maintenance of the transformed phenotype and that decreasing transcription of the HAAH gene or decreasing enzymatic activity of the HAAH gene product leads to a decrease in malignancy. Accordingly, HAAH transcription is inhibited by administering compounds which decrease binding of Fos and/or Jun (elements which regulate HAAH transcription) to HAAH promoter sequences.

[0104] Since HAAH is up-regulated with malignant transformation of bile duct epithelium, and HAAH immunoreactivity is detectable on tumor cell surface membranes, HAAH is also a molecule to which to target a cytotoxic agent, e.g., by linking the cytotoxic agent to a compound that binds to HAAH expressed on the surface of a tumor cell. Assay of HAAH protein levels in either biological fluids such as bile, or cells obtained by fine needle aspiration is a diagnostic marker of human cholangiocarcinoma.

EXAMPLE 2

Expression of AAH and Growth and Invasiveness of Malignant CNS Neoplasms

[0105] AAH is abundantly expressed in carcinomas and trophoblastic cells, but not in most normal cells, including those of CNS origin. High levels of AAH expression were observed in 15 of 16 glioblastomas, 8 of 9 anaplastic oligodendrogliomas, and 12 of 12 primitive neuroectodermal tumors (PNETs). High levels of AAH immunoreactivity were primarily localized at the infiltrating edges rather than in the central portions of tumors. Double-label immunohistochemical staining demonstrated a reciprocal relationship between AAH and tenascin, a substrate for AAH enzyme activity. PNET2 neuronal cell lines treated with phorbol ester myristate or retinoic acid to stimulate neurite extension and invasive growth exhibited high levels of AAH expression, whereas H_2O_2 -induced neurite retraction resulted in down-regulation of AAH. PNET2 neuronal cells that stably over-expressed the human AAH cDNA had increased levels of PCNA and Bcl-2, and reduced levels of p21/Waf1 and p16, suggesting that AAH overexpression results in enhanced pathological cell proliferation, cell cycle progression, and resistance to apoptosis. In addition, the reduced levels of p16 observed in AAH-transfectants indicate that AAH over-expression confers enhanced invasive growth of neoplastic cells since deletion or down-regulation of the p16 gene correlates with more aggressive and invasive *in vivo* growth of glioblastomas. Increased AAH immunoreactivity was detected at the infiltrating margins of primary malignant CNS neoplasms, further indicating a role of HAAH in tumor invasiveness.

[0106] The following materials and methods were used to generate the data described below.

[0107] Analysis of AAH Immunoreactivity in Primary Human Malignant CNS Neoplasms:

[0108] AAH immunoreactivity was examined in surgical resection specimens of glioblastoma (N=16), anaplastic oligodendroglioma (N=9), and primitive neuroectodermal tumor (PNET; supratentorial neuroblastomas (N=3) and medulloblastomas (N=9)). The histopathological sections were reviewed to confirm the diagnoses using standard criteria. Paraffin sections from blocks that contained representative samples of viable solid tumor, or tumor with adjacent intact tissue were studied. Sections from normal adult postmortem brains (N=4) were included as negative controls. AAH immunoreactivity was detected using an HAAH-specific monoclonal antibody. Immunoreactivity was revealed by the avidin-biotin horseradish peroxidase complex method (Vector ABC Elite Kit; Vector Laboratories, Burlingame, CA) using 3-3' diaminobenzidine (DAB) as the chromogen (24) and hematoxylin as a counterstain.

[0109] Tenascin and laminin are likely substrates for AAH due to the presence of EGF-like repeats within the molecules. Double-immunostaining studies were performed to co-localize AAH with tenascin or laminin. The AAH immunoreactivity was detected by the ABC method with DAB as the chromogen, and tenascin or laminin immunoreactivity was detected by the avidin-biotin alkaline phosphatase complex method (Vector Laboratories, Burlingame, Calif.) with BCIP/NBT as the substrate. As positive and negative controls, adjacent sections were immunostained with monoclonal antibody to glial fibrillary acidic protein (GFAP) and Hepatitis B surface antigen. All specimens were batch immunostained using the same antibody dilutions and immunodetection reagents.

[0110] Cell Lines and Culture Conditions

[0111] Studies were conducted to determine whether AAH expression was modulated with neurite (filopodia) extension (sprouting) as occurs with invasive growth of malignant neoplasms. Human PNET2 CNS-derived and SH-Sy5y neuroblastoma cells were cultured and stimulated for 0, 1, 2, 3, 5, or 7 days with 100 nM phorbol 12-ester 13-acetate or 10 μ M retinoic acid to induce sprouting. In addition, to examine the effects of neurite retraction on AAH expression, subconfluent cultures were treated for 24 hours with low concentrations (10-40 μ M) of H₂O₂. For both studies, AAH expression was evaluated by Western blot analysis using the an HAAH-specific antibody.

[0112] Generation of PNET2 AAH-transfected Clones

[0113] The full-length human AAH cDNA (SEQ ID NO:3) was ligated into the pcDNA3.1 mammalian expression vector in which gene expression was under the control of a CMV promoter (Invitrogen Corp., San Diego, Calif.). PNET2 cells were transfected with either pHAAH or pcDNA3 (negative control) using Cellfectin reagent (Gibco BRL, Grand Island, N.Y.). Neomycin-resistant clones were selected for study if the constitutive levels of AAH protein expression were increased by at least two-fold relative to control (pcDNA3) as detected by Western blot analysis. To determine how AAH overexpression altered the expression of genes that modulate the transformed phenotype, the levels of proliferating cell nuclear antigen (PCNA), p53, p21/Waf1, Bcl-2, and p16 were measured in cell lysates prepared from subconfluent cultures of AAH (N=5) and pcDNA3

(N=5) stably transfected clones. PCNA was used as marker of cell proliferation. p53, p21/Waf1, and Bcl-2 levels were examined to determine whether cells that over-expressed AAH were more prone to cell cycle progression and more resistant to apoptosis. The levels of p16 were assessed to determine whether AAH over-expression has a role in tumor invasiveness.

[0114] Western Blot Analysis

[0115] Cells grown in 10 cm² dishes were lysed and homogenized in a standard radioimmunoprecipitation assay RIPA buffer containing protease and phosphatase inhibitors. The supernatants collected after centrifuging the samples at 12,000x g for 10 minutes to remove insoluble debris were used for Western blot analysis. Protein concentration was measured using the BCA assay (Pierce Chemical Co, Rockford, Ill.). Samples containing 60 μ g of protein were electrophoresed in sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) and subjected to Western blot analysis. Replicate blots were probed with the individual antibodies. Immunoreactivity was detected with horseradish peroxidase conjugated IgG (Pierce Chemical Co, Rockford, Ill.) and enhanced chemiluminescence reagents. To quantify the levels of protein expression, non-saturated autoradiographs were subjected to volume densitometry using NIH Image software, version 1.6. Statistical comparisons between pHAAH and pcDNA3 transfected cells were made using Student T tests.

[0116] Antibodies

[0117] HAAH-specific monoclonal antibody generated against the FOCUS hepatocellular carcinoma cells were used to detect AAH immunoreactivity. Monoclonal antibodies to tenascin, and glial fibrillary acidic protein, and rabbit polyclonal antibody to laminin were purchased from Sigma Co (St. Louis, Mo.). Rabbit polyclonal antibody to human p16 was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, Calif.). The 5C3 negative control monoclonal antibody to Hepatitis B surface antigen was generated using recombinant protein and used as a negative control.

[0118] AAH Immunoreactivity in Primary Malignant Brains Tumors

[0119] AAH immunoreactivity was detected in 15 of 16 glioblastomas, 8 of 9 anaplastic oligodendrogliomas, and all 12 PNETs. AAH immunoreactivity was localized in the cytoplasm, nucleus, and cell processes. The tissue distribution of AAH immunoreactivity was notable for the intense labeling localized at the interfaces between tumor and intact brain, and the conspicuously lower levels of immunoreactivity within the central portions of the tumors. High levels of AAH immunoreactivity were also observed in neoplastic cells distributed in the subpial zones, leptomeninges, Virchow-Robin perivascular spaces, and in individual or small clusters of neoplastic cells that infiltrated the parenchyma. In contrast, AAH immunoreactivity was not detectable in normal brain. The distribution of AAH immunoreactivity appeared not to be strictly correlated with DNA synthesis since the density of nuclei in mitosis (1-5%) was similar in the central and peripheral portions of the tumors.

[0120] Relationship Between AAH and Tenascin Immunoreactivity in Glioblastomas

[0121] Tenascin is an extracellular matrix-associated antigen expressed in malignant gliomas. Tenascin contains

EGF-like domains within the molecule, a substrate for HAAH hydroxylation. To localize AAH in relation to tenascin immunoreactivity in malignant brain tumors, double-label immunohistochemical staining was performed in which AAH was detected using a brown chromogen (DAB), and tenascin, a blue chromogen (BCIP/NBT). Adjacent sections were similarly double-labeled to co-localize AAH with laminin, another EGF domain containing extracellular matrix molecule expressed in the CNS. Intense levels of tenascin immunoreactivity were observed in perivascular connective tissue and in association with glomeruloid proliferation of endothelial cells. The double-labeling studies demonstrated a reciprocal relationship between AAH and tenascin immunoreactivity such that high levels of AAH were associated with low or undetectable tenascin, and low levels of AAH were associated with abundant tenascin immunoreactivity. Although laminins are also likely substrates for AAH enzyme activity due to the EGF repeats within the molecules, double labeling studies revealed only low levels of laminin immunoreactivity throughout the tumors and at interfaces between tumor and intact tissue.

[0122] Analysis of AAH Expression in Neuronal Cell Lines Treated with PMA or RA

[0123] Neuritic sprouting/filopodia extension marks invasive growth of neoplastic neuronal cells. PMA activates protein kinase C signal transduction pathways that are involved in neuritic sprouting. Retinoic acid binds to its own receptor and the ligand-receptor complex translocates to the nucleus where it binds to specific consensus sequences present in the promoter/enhancer regions of target genes involved in neuritic growth. Both PNET2 and SH-Sy5y cells can be induced to sprout by treatment with PMA (60-120 nM) or retinoic acid (5-10 μ M). FIGS. 5A-D depict data from representative Western blot autoradiographs; the bar graphs correspond to the mean \pm S.D. of results obtained from three experiments. Western blot analysis with the FB50 antibody detected doublet bands corresponding to protein with an molecular mass of approximately 85 kDa. Untreated PNET2 cells had relatively low levels of AAH immunoreactivity (FIG. 5A), whereas untreated SH-Sy5y cells had readily detected AAH expression (FIG. 5B). Untreated PNET2 cells exhibited polygonal morphology with coarse, short radial cell processes, whereas SH-Sy5y cells were slightly elongated and spontaneously extend fine tapered processes. Both cell lines manifested time-dependent increases in the levels of AAH immunoreactivity following either RA (FIGS. 5A and 5B) or PMA (FIG. 5C) stimulation and neurite extension. In PNET2 cells, the levels of AAH protein increased by at least two-fold 24 hours after exposure to RA or PMA, and high levels of AAH were sustained throughout the 7 days of study. In SH-Sy5y cells, the RA- or PMA-stimulated increases in AAH expression occurred more gradually and were highest after 7 days of treatment (FIG. 5B).

[0124] To examine the effect of AAH expression on neurite retraction, PNET2 and SH-Sy5y cells were treated with low concentrations (8-40 μ M) of H₂O₂. After 24 hours exposure to up to 40 μ M H₂O₂, although most cells remained viable (Trypan blue dye exclusion), they exhibited neurite retraction and rounding. Western blot analysis using the FB50 antibody demonstrated H₂O₂ dose-dependent reductions in the levels of AAH protein (FIG. 5D).

[0125] Effects of AAH Over-expression in PNET2 Cells

[0126] To directly assess the role of AAH overexpression in relation to the malignant phenotype, PNET2 cells were stably transfected with the human full-length cDNA with gene expression under control of a CMV promoter (pHAAH). Neomycin-resistant clones that had at least two-fold higher levels of AAH immunoreactivity relative to neomycin-resistant pcDNA3 (mock) clones were studied. Since aggressive behavior of malignant neoplasms is associated with increased DNA synthesis, cell cycle progression, resistance to apoptosis, and invasive growth, the changes in phenotype associated with constitutive over-expression of AAH were characterized in relation to PCNA, p21/Waf1 p53, Bcl-2, and p16. PCNA was used as an index of DNA synthesis and cell proliferation. p21/Waf1 is a cell cycle inhibitor. Expression of the p53 tumor-suppressor gene increases prior to apoptosis, whereas bcl-2 inhibits apoptosis and enhances survival of neuronal cells. p16 is an oncosuppressor gene that is often either down-regulated or mutated in infiltrating malignant neoplasms.

[0127] Five pHAAH and 5 pcDNA3 clones were studied. Increased levels of AAH expression in the pHAAH transfected clones was confirmed by Western (FIG. 6) and Northern blot analyses. Western blot analysis using cell lysates from cultures that were 70 to 80 percent confluent demonstrated that constitutively increased levels of AAH expression (approximately 85 kDa; $P < 0.05$) in pHAAH-transfected cells were associated with significantly increased levels of PCNA (approximately 35 kDa; $P < 0.01$) and Bcl-2 (approximately 25 kDa; $P < 0.05$), and reduced levels of p21/Waf1 (approximately 21 kDa; $P < 0.001$) and p16 (approximately 16 kDa; $P < 0.001$) (FIG. 6). However, the pHAAH stable transfectants also exhibited higher levels of wild-type p53 (approximately 53-55 kDa). Although AAH expression (85 kDa protein) in the stable transfectants was increased by only 75 to 100 percent, the levels of p16 and p21/Waf1 were sharply reduced, and PCNA increased by nearly two-fold (FIG. 6).

[0128] Increased AAH Expression is Indicative of Growth and Invasiveness of Malignant CNS Neoplasms

[0129] The data described herein demonstrates that AAH overexpression is a diagnostic tool by which to identify primary malignant CNS neoplasms of both neuronal and glial cell origin. Immunohistochemical staining studies demonstrated that AAH overexpression was detectable mainly at the interfaces between solid tumor and normal tissue, and in infiltrating neoplastic cells distributed in the subpial zones, leptomeninges, perivascular spaces, and parenchyma. In vitro experiments demonstrated that AAH gene expression was modulated with neurite (filopodium) extension and invasiveness and down-regulated with neurite retraction. In addition, PNET2 cells stably transfected with the AAH cDNA exhibited increased PCNA and bcl-2, and reduced Waf1/p21 and p16 expression. Therefore, AAH overexpression contributes to the transformed phenotype of CNS cells by modulating the expression of other genes that promote cellular proliferation and cell cycle progression, inhibit apoptosis, or enhance tumor cell invasiveness.

[0130] The data demonstrated readily detectable AAH mRNA transcripts (4.3 kB and 2.6 kB) and proteins (85 kDa and 50-56 kDa) in PNET2 and SH-Sy5y cells, but not in normal brain. Correspondingly, high levels of AAH immunoreactivity were observed in 35 of the 37 in malignant

primary CNS-derived neoplasms studied, whereas the 4 normal control brains had no detectable AAH immunoreactivity. The presence of high-level AAH immunoreactivity at the infiltrating margins and generally not in the central portions of the tumors indicates that AAH overexpression is involved in the invasive growth of CNS neoplasms. Administration of compounds which decrease AAH expression or enzymatic activity inhibits proliferation of CNS tumors which overexpress AAH, as well as metastases of CNS tumors to other tissue types.

[0131] The AAH enzyme hydroxylates EGF domains of a number of proteins. Tenascin, an extracellular matrix molecule that is abundantly expressed in malignant gliomas, contains EGF-like domains. Since tenascin promotes tumor cell invasion, its abundant expression in glioblastomas represents an autocrine mechanism of enhanced tumor cell growth vis-à-vis the frequent overexpression of EGF or EGF-like receptors in malignant glial cell neoplasms. Analysis of the functional domains of tenascins indicated that the mitogenic effects of this family of molecules are largely mediated by the fibronectin domains, and that the EGF-like domains inhibit growth, cell process elongation, and matrix invasion. Therefore, hydroxylation of the EGF-like domains by AAH represents an important regulatory factor in tumor cell invasiveness.

[0132] Double-label immunohistochemical staining studies demonstrated a reciprocal relationship between AAH and tenascin immunoreactivity such that high levels AAH immunoreactivity present at the margins of tumors were associated with low levels of tenascin, and low levels of AAH were often associated with high levels of tenascin. These observations indicated that AAH hydroxylation of EGF-like domains of tenascin alters the immunoreactivity of tenascin protein, and in so doing, facilitates the invasive growth of malignant CNS neoplasms into adjacent normal tissue and perivascular spaces.

[0133] AAH immunoreactivity was examined in PNET2 and SH-Sy5y neuronal cells induced to undergo neurite extension with PMA or retinoic acid, or neurite retraction by exposure to low doses of H₂O₂. AAH expression was sharply increased by PMA- or retinoic acid-induced neurite (filopodium) extension, and inhibited by H₂O₂-induced neurite retraction and cell rounding. Neurite or filopodium extension and attachment to extracellular matrix are required for-tumor cell invasion in the CNS. The EGF-like domains of tenascin inhibit neuritic and glial cell growth into the matrix during development.

[0134] To directly examine the role of AAH overexpression in relation to the transformed phenotype, genes modulated with DNA synthesis, cell cycle progression, apoptosis, and tumor invasiveness were examined in neuronal cell clones that stably over-expressed the human AAH cDNA. The findings of increased PCNA and reduced Waf1/p21 immunoreactivity indicated that AAH overexpression enhances cellular proliferation and cell cycle progression. In addition, the finding of increased Bcl-2 expression indicated that AAH overexpression contributes to the transformed phenotype by increasing cellular resistance to apoptosis. The

apparently contradictory finding of higher levels of p53 in the cells that overexpressed AAH is explained by the observation that high levels of wildtype p53 in immature neuronal cells were associated with neuritic growth (invasiveness) rather than apoptosis. Levels of p16 were reduced (compared to normal cells) or virtually undetectable in cells that constitutively overexpressed AAH; a deletion mutation of the p16 gene has been correlated with invasive growth and more rapid progression of malignant neoplasms, including those of CNS origin. These data indicate that p16 expression is modulated by AAH.

EXAMPLE 3

Increased HAAH Production and IRS-mediated Signal Transduction

[0135] IRS-1 mediated signal transduction pathway is activated in 95% of human HCC tumors compared to the adjacent uninvolved liver tissue. HAAH is a downstream effector gene involved in this signal transduction pathway. HAAH gene upregulation is closely associated with overexpression of IRS-1 in HCC tumors as revealed by immunohistochemical staining and Western blot analysis. A high level of HAAH protein is expressed in HCC and cholangiocarcinoma compared to normal hepatocytes and bile ducts. Both of these tumors also exhibit high level expression of IRS-1 by immunohistochemical staining. FOCUS HCC cell clones stably transfected with a C-terminal truncated dominant negative mutant of IRS-1, which blocks insulin and IGF-1 stimulated signal transduction, was associated with a striking reduction in HAAH gene expression in liver. In contrast, transgenic mice overexpressing IRS-1 demonstrate an increase in HAAH gene expression by Western blot analysis. Insulin stimulation of FOCUS HCC cells (20 and 40 U) in serum free medium and after 16 hr of serum starvation demonstrated upregulation of HAAH gene expression. These data indicate that HAAH gene expression is a downstream effector of the IRS-1 signal transduction pathway.

EXAMPLE 4

Effects of HAAH Expression Levels on the Characteristics of the Malignant Phenotype

[0136] Overexpression of IRS-1 in NIH 3T3 cells induces transformation. The full-length murine HAAH construct was cloned into the pcDNA3 eukaryotic expression vector. A second murine construct encoded HAAH with abolished catalytic activity due to a site directed mutation. The full-length human HAAH cDNA was cloned into the pcDNA3 expression vector as well as a plasmid that encodes v-src which was used as a positive control for transformation activity. Standard methods were used for transfection of NIH 3T3 cells, control for transfection efficiency, assays of HAAH enzymatic activity, transformation by analysis of foci formation, anchorage-independent cell growth assays and analysis of tumorigenicity in nude mice. The data indicated that HAAH overexpression is associated with generation of a malignant phenotype.

Table 4
Overexpression of Enzymatically Active HAAH
Indicates Malignancy
[0137]

cDNA	# of foci ± S.D. ^b	NIH 3T3 clone	# of colonies ^c
pcDNA3 (mock)	6.0 ± 3.3	pcDNA (mock)	0.4 ± 0.5
murine HAAH	14.0 ± 2.9	clone 18 ^d	6.2 ± 2.9
mutant murine HAAH ^a	1.6 ± 1.0	clone 16 ^e	4.7 ± 6.5
human HAAH	32.0 ± 5.4		
v-scr	98.0 ± 7.1		

^aenzymatically inactive HAAH
^bP < 0.01 compared to mock and mutant murine HAAH
^cP < 0.001 compared to mock
^dClone 18 is a stable cloned NIH 3T3 cell line that overexpression human HAAH by approximately two fold.
^eClone 16 is a stable cloned NIH 3T3 cell line that overexpresses human HAAH by about 50%.

[0138] These data indicate that overexpression of HAAH is associated with formation of transformed foci. Enzymatic activity is required for cellular transformation to occur.
[0139] Cloned NIH 3T3 cell lines with increased human HAAH gene expression grew as solid tumors in nude mice. HAAH is a downstream effector gene of the IRS-1 signal transduction pathway.

EXAMPLE 5

Inhibition of HAAH Gene Expression

[0140] The FOCUS HCC cell line from which the human HAAH gene was initially cloned has a level of HAAH expression that is approximately 3-4 fold higher than that found in normal liver. To make an HAAH antisense construct, the full length human HAAH cDNA was inserted in the opposite orientation into a retroviral vector containing a G418 resistant gene, and antisense RNA was produced in the cells. Shorter HAAH antisense nucleic acids, e.g., those corresponding to exon 1 of the HAAH gene are also used to inhibit HAAH expression.
[0141] FOCUS cells were infected with this vector and the level of HAAH was determined by Western blot analysis. A

reduction in HAAH gene expression was observed. Growth rate and morphologic appearance of cells infected with a retrovirus containing a nonrelevant Green Fluorescent Protein (GFP) also inserted in the opposite orientation as a control (FIG. 8). Cells (harboring the HAAH antisense construct) exhibited a substantial change in morphology characterized by an increase in the cytoplasm to nuclear ratio as well as assuming cell shape changes that were reminiscent of normal adult hepatocytes in culture. Cells with reduced HAAH levels grew at a substantially slower rate than retroviral infected cells expressing antisense (GFP) (control) as shown in FIG. 8. A reduction in HAAH gene expression was associated with a more differentiated non-cancerous "hepatocyte like" phenotype. Expression of HAAH antisense sequences are used to inhibit tumor growth rate. Reduction of HAAH cellular levels results in a phenotype characterized by reduced formation of transformed foci, low level or absent anchorage independent growth in soft agar, morphologic features of differentiated hepatocytes as determined by light and phase contrast microscopy, and no tumor formation (as tested by inoculating the cells into nude mice).

EXAMPLE 6

Human IRS-1 Mutants

[0142] Insulin/IGF-1 stimulated expression of HAAH in HCC cell lines. Dominant-negative IRS-1 cDNAs mutated in the plextrin and phosphotyrosine (PTB) domains, and Grb2, Syp and PI3K binding motifs located in the C-terminus of the molecule were constructed. Human IRS-1 mutant constructs were generated to evaluate how HAAH gene expression is upregulated by activation of the IRS-1 growth factor signal transduction cascade. Specific mutations in the C terminus of the hIRS-1 molecule abolished the various domains which bind to SH2-effector proteins such as Grb2, Syp and PI3K. The human IRS-1 protein contains the same Grb2 and Syp binding motifs of 897YVNI (underlined in Table 5, below and 1180YIDL (underlined in Table 5, below), respectively, as the rat IRS-1 protein. Mutants of hIRS-1 were constructed by substitution of a TAT codon (tyrosine) with a TTT codon (phenylalanine), in these motifs by use of oligonucleotide-directed mutagenesis using the following primers: (5'-GGGGGAATTTGTCAATA-3' (SEQ ID NO:8) and 5'-GAATTTGTTAATATTG-3' (SEQ ID NO:9), respectively). The cDNAs of hIRS-1 (wild-type) and mutants (tyrosine 897-to-phenylalanine and tyrosine 1180-to-phenylalanine) were subcloned into the pBK-CMV expression vector and designated as hIRS-1-wt, 897F, Δ-Grb2), 1180F, and ΔSyp.

TABLE 5

Human IRS-1 amino acid sequence	
MASPPESDGF SDVRKVGYLK KPKSMHKRFF VLRAASEAGG PARLEYEENE KKRHRKSSAP	61
KRSIPLESCF NINKRADSKN KHLVALYTRD EHFAIAADSE AEQDSWYQAL LQLHNRAKGH	121
HDGAAALGAG GGGGSCSGSS GLGEAGEDLS YGDVPPGPAP KEVWQVILKP KGLGQTKNLI	181
GIYRLCLTSK TISFVKLNSE AAAVVLQLMN IRRCGHSENF FFIEVGRSAV TGPGEFWMQV	241
DDSVVAQNMH ETILEAMRAM SDEFRPRSKS QSSSNCSNPI SVPLRRHHLN NPPPSQVGLT	301

TABLE 5-continued

Human IRS-1 amino acid sequence		
RRSRTESITA TSPASMVGGK PGsFRVRASS DGEgTMSRPA SVDGSPVSPS TNrTHAHRHR	361	
GSARLHPPLN HSRsIPMPAS RCSPSATSPV SLSSSSTSGH GSTSDCLFPR RSSASVSGSP	421	
SDGGFISSDE YGSSPCDFRS SFRSVTPDSL GHTPPARGEE ELSNYICMGg KGPSTLTAPN	481	
GHYILSRGGN GHRCTPGTGL GTSPALAGDE AASAADLDNR FRKRTHSAGT SPTITHQKTP	541	
SQSSVASIEE YTEMPAYPP GGGSGGRLPG HRHSAFVPTR SYPEEGLEMH PLERRGGHHR	601	
PDSSTLHTDD GYMPMSPGVA PVPsGRKGSG DYMPMSPKSV SAPQQIINPI RRHPQRVDPN	661	
GYMMMSPSGG CSPDIGGGS SSSSSSNAVp SGTsYGKLWT NGVGGHSHV LPHPKPPVES	721	
SGGKLLPCTG DYMNMSPGVD SNTSSPSDCY YGPEDPQHkP VLSYsSLPRS FKHTQRPGEP	781	
EEGARHQHLR LSTSSGRLLY AATADDSSSS TSSDSLGGGY CGARLEPSLP HPHHQVLQPH	841	
LPRKVDTAAG TNSRLARPTR LSLGDPKAST LPRAREQQQQ QPPLLHPPEP KSPGEYVNI	901	
FGSDQSGYLS GPVAFHSSPS VRCPSQLQPA PREETGTEE YMKMDLGPGR RAAWQESTGV	961	
EMGRLGPAPP GAASICRPTR AVPSsRGDYM TMQMSCPRQS YVDTSPAAPV SYADMRTGIA	1021	
AEVSLPRAT MAASSSSAA SASPTGPQGA AELAAHSSL GGPQGPGGMS AFTRVNLSPN	1081	
RNQSAKVIRA DPQGCRRRS SETFSSTPSA TRVGNTVPFG AGAAVGGGGG SSSSSEdVKR	1141	
HSSASFENVW LRPgELGGAP KEPAKLCGAA GLENGLNI DLDLVKDFKQ CPQECTPEPQ	1201	
PPPPPPPHQF LGSGESSSTR RSSEdLSAYA SISFQKQPED RQ		

(SEQ ID NO:5; GENBANK Accession No. J50670; pleckstrin domain spans residues 11-113, inclusive; Phosphate-binding residues include 46, 465, 551, 612, 632, 662, 732, 941, 989, or 1012 of SEQ ID NO:5)

[0143]

TABLE 6

Human IRS-1 cDNA		
cggcggcgcg gtcgcgaggg gccggcgcgc agagccagac gccgccgctt gttttggttg	61	
gggctctcgg caactctccg aggaggagga ggaggaggga ggaggggaga agtaactgca	121	
gcggcagcgc cctcccaggg aacaggcgtc tccccgaac ccttccaaa cctcccccat	181	
ccctctcgc cctgtctccc tcccctctc cccagccgcc tggagcgagg ggcagggatg	241	
agtctgtccc tccggccggt cccagctgc agtggctgcc cgttatcgtt tcgcatggaa	301	
aagccacttt ctccaccgcg cgagatgggc ccggatgggg ctgcagagga cgcgcccgcg	361	
ggcggcggca gcagcagcag cagcagcagc agcaacagca acagccgcag gcgcgcggtc	421	
tctgcgactg agctgggtatt tggggcgctg gtggcggtg ggacggttg ggggtgggag	481	
gaggcgaagg aggagggaga accccgtgca acgttgggac ttggcaacct gcctccccct	541	
gcccaggat atttaatttg cctcggaat cgctgcttcc agaggggaac tcaggaggga	601	
aggcgcgcgc gcgcgcgcgc tcctggaggg gcaccgcagg gacccccgac tgtcgccctc	661	
ctgtgcccga ctccagccgg ggcgacgaga gatgcatctt cgctccttcc tgggtggcgc	721	
ggcggctgag aggagacttg gctctcgag gatcggggct gccctcacc cggacgcact	781	
gcctccccgc cggcgtaga cgccgaaaa ctccggtcgg gctctctcct gggctcagca	841	

TABLE 6-continued

Human IRS-1 cDNA	
gctgcgtcct ccttcagctg cccctccccg gcgcgggggg cgcggtggat ttcagagtcg	901
gggtttctgc tgctccagc cctgcttgca tgtgccgggc cgcggcgagg agcctccgcc	961
ccccaccggg ttgtttttcg gagcctccct ctgctcagcg ttggtggtgg cggtggcagc	1021
atggcgagcc ctccggagag cgatggcttc tcggacgtgc gcaaggtggg ctacctgcgc	1081
aaaccaaga gcatgcacaa acgcttcttc gtactgcgcg cgccacagca ggctgggggc	1141
ccggcgcgcc tcgagtacta cgagaacgag aagaagtggc ggcacaagtc gagcgccccc	1201
aaacgctcga tcccccttga gagctgcttc aacatcaaca agcgggctga ctccaagaac	1261
aagcacctgg tggctctcta caccgggac gagcactttg ccatcgcgga ggacagcgag	1321
gccgagcaag acagctggta ccaggctctc ctacagctgc acaaccgtgc taagggccac	1381
cacgacggag ctgcggccct cggggcggga ggtggtggg gcagctgcag cggcagctcc	1441
ggccttggtg aggtgggga ggacttgagc tacggtgacg tgccccagc acccgcattc	1501
aaagaggtct ggcaagtgat cctgaagccc aagggcctgg gtcagacaaa gaacctgatt	1561
ggtatctacc gcctttgcct gaccagcaag accatcagct tcgtgaagct gaactcggag	1621
gcagcgcccg tgggtctgca gctgatgaac atcaggcgct gtggccactc ggaaaacttc	1681
ttcttcacatc aggtggggcg ttctgcgtg acggggcccg gggagttctg gatgcagtg	1741
gatgactctg tggtgggcca gaacatgcac gagaccatcc tggaggccat gcgggccaatg	1801
agtgatgagt tccgccctcg cagcaagagc cagtcctcgt ccaactgctc taacccatc	1861
agcgtccccc tgcgcggcca ccatctcaac aatccccgc ccagccaggt ggggctgacc	1921
cgccgatcac gcaactgagag catcacccgc acctccccgg ccagcatggt gggcgggaag	1981
ccaggctcct tccgtgtccg cgctccagt gacggcgaag gcaccatgtc ccgcccagcc	2041
tcggtgagc gcagccctgt gagtccagc accaacagaa ccacgccc cgggcatcgg	2101
ggcagcgccc ggctgcaccc cccgctcaac cacagccgct ccatcccat gccggcttcc	2161
cgtgctcgc cttcgccac cagcccggtc agtctgtcgt ccagtagcac cagtggccat	2221
ggctccacct cggattgtct cttcccacgg cgatctagtg cttcgggtgc tggttcccc	2281
agcgatggcg gtttcatctc ctcgatgag tatggctcca gtccctgcga ttccggagt	2341
tccttcgcga gtgtactcc ggattccctg ggccacacc caccagccc cggtgaggag	2401
gagctaagca actatatctg catgggtggc aaggggcct caccctgac ccccccaac	2461
ggtcactaca ttttgtctcg ggtggcaat ggccaccgct gcacccagc aacaggcttg	2521
ggcacgagtc cagccttggc tggggatgaa gcagccagtg ctgcagatct ggataatcg	2581
ttccgaaaga gaactcactc ggcaggcaca tcccctacca ttaccacca gaagacccg	2641
tcccagtcct cagtggcttc cattgaggag tacacagaga tgatgcctgc ctaccacca	2701
ggaggtggga ttggaggcgc actgcggga cacaggcact ccgccttcgt gccacccgc	2761
tcctacccag aggagggtct ggaatgcac cccttgagc gtcggggggg gcaccaccgc	2821
ccagacagct ccacctcca cagggatgat ggctacatgc ccatgtcccc aggggtggcc	2881
ccagtgccta ttggccgaaa gggcagtgga gactatatgc ccatgagccc caagagcgta	2941
tctgcccac agcagatcat caatccatc agacgccatc ccagagagt ggaccccaat	3001
ggctacatga tgatgtcccc cagcggtggc tgctctcctg acattggagg tggcccagc	3061

TABLE 6-continued

Human IRS-1 cDNA							
agcagcagca	gcagcagcaa	cgccgtccct	tccgggacca	gctatggaaa	gctgtggaca	3121	
aacggggtag	ggggccacca	ctctcatgtc	ttgcctcacc	ccaaaccccc	agtggagagc	3181	
agcggtggtg	agctcttacc	ctgcacaggt	gactacatga	acatgtcacc	agtgggggac	3241	
tccaacacca	gcagcccctc	cgactgctac	tacggccctg	aggaccccca	gcacaagcca	3301	
gtcctctcct	actactcatt	gccaaagatcc	tttaagcaca	cccagcgccc	cggggagccg	3361	
gaggaggggtg	cccggcatca	gcacctccgc	ctttccacta	gctctgggtcg	ccttctctat	3421	
gctgcaacag	cagatgattc	ttcctcttcc	accagcagcg	acagcctggg	tgggggatac	3481	
tgcggggcta	ggctggagcc	cagccttcca	catccccacc	atcaggttct	gcagccccat	3541	
ctgcctcgaa	aggtggacac	agctgctcag	accaatagcc	gcctggcccg	gcccacgagg	3601	
ctgtccctgg	gggatcccaa	ggccagcacc	ttacctcggg	cccagagagca	gcagcagcag	3661	
cagcagccct	tgtctgaccc	tccagagccc	aagagcccgg	gggaatatgt	caatattgaa	3721	
tttgggagtg	atcagtctgg	ctacttgtct	ggcccgggtg	ctttccacag	ctcaccttct	3781	
gtcagtggtc	catcccagct	ccagccagct	cccagagagg	aagagactgg	cactgaggag	3841	
tacatgaaga	tggacctggg	gccgggcccg	agggcagcct	ggcaggagag	cactggggtc	3901	
gagatgggca	gactggggcc	tgcacctccc	ggggctgcta	gcatttgag	gcctaccggg	3961	
gcagtgccca	gcagccgggg	tgactacatg	accatgcaga	tgagttgtcc	ccgtcagagc	4021	
tacgtggaca	cctcgccagc	tgcccctgta	agctatgctg	acatgcgaac	aggcattgct	4081	
gcagaggagg	tgagcctgcc	caggggccacc	atggctgctg	cctcctcacc	ctcagcagcc	4141	
tctgcttccc	cgactggggc	tcaaggggca	gcagagctgg	ctgcccactc	gtccctgctg	4201	
ggggggccac	aaggacctgg	gggcatgagc	gccttcaccc	gggtgaacct	cagtcctaac	4261	
cgcaaccaga	gtgcaaaagt	gatccgtgca	gacccacaag	ggtgccggcg	gaggcatagc	4321	
tccgagactt	tctcctcaac	accagtgccc	acccgggtgg	gcaacacagt	gccctttgga	4381	
gcgggggcag	cagtaggggg	cggtggcggg	agcagcagca	gcagcgagga	tgtgaaacgc	4441	
cacagctctg	cttcctttga	gaatgtgtgg	ctgaggcctg	gggagcttgg	gggagccccc	4501	
aaggagccag	ccaaactgtg	tggggctgct	gggggtttgg	agaatgggtct	taactacata	4561	
gacctggatt	tgggtcaagg	cttcaaacag	tgccctcagg	agtgcacccc	tgaaccgcag	4621	
cctccccccac	ccccaccccc	tcatcaaccc	ctgggcagcg	gtgagagcag	ctccacccgc	4681	
cgctcaagtg	aggatttaag	cgcctatgcc	agcatcagtt	tccagaagca	gccagaggac	4741	
cgtcagtagc	tcaactggac	atcacagcag	aatgaagacc	taaatgacct	cagcaaatcc	4801	
tcttctaact	catgggtacc	cagactctaa	atatttcatg	attcacaact	aggacctcat	4861	
atcttctcca	tcagtagatg	gtacgatgca	tccatttcag	tttgtttact	ttatccaatc	4921	
ctcaggattt	cattgactga	actgcacgtt	ctatattgtg	ccaagcgaaa	aaaaaaaaatg	4981	
cactgtgaca	ccagaataat	gagttctgcat	aaacttcac	ttcaacctta	aggacttagc	5041	
tggccacagt	gagctgatgt	gcccaccacc	gtgtcatgag	agaatgggtt	tactetcaat	5101	
gcattttcaa	gatacatctt	atctgctgct	gaaactgtgt	acgacaaagc	atcattgtaa	5161	
attatttcat	acaaaactgt	tcacgttggg	tggagagagt	attaaatatt	taacataggt	5221	
tttgatttat	atgtgtaatt	ttttaaatga	aaatgtaact	tttcttacag	cacatctttt	5281	

TABLE 6-continued

Human IRS-1 cDNA	
ttttggatgt gggatggagg tatacaatgt tctgttgtaa agagtggagc aaatgcttaa	5341
aacaaggcctt aaaagagtag aatagggtat gatccttggt ttaagattgt aattcagaaa	5401
acataatata agaatacatag tgccatagat ggttctcaat tgtatagtta tatttgctga	5461
tactatctct tgtcatataa acctgatgtt gagctgagtt ccttataaga attaatctta	5521
attttgtatt ttttctgtga agacaatagg ccatgttaat taaactgaag aaggatatat	5581
ttggctgggt gttttcaaat gtcagcttaa aattggtaat tgaatggaag caaaattata	5641
agaagaggaa attaaagtct tccattgcat gtattgtaaa cagaaggaga tgggtgattc	5701
cttcaattca aaagctctct ttggaatgaa caatgtgggc gtttgtaa tctggaaatg	5761
tctttctatt cataataaac tagatactgt tgatcttitta aaaaaaaaaa aaaaaaaaaa	5821
aaaaaaaa	
(SEQ ID NO:6; GENBANK Accession No. NM 005544)	

[0144] The double mutation of tyrosine 897 and 1180 was constructed by replacement of 3'-sequences coding 897F by the same region of 1180F using restriction enzymes NheI and EcoRI, and this construct was called 897F1180F or ΔGrb2 ΔSyp. The expression plasmids were under control of a CMV promoter (hIRS-1-wt, ΔGrb2, ΔSyp, ΔGrb2, ΔSyp and PBK-CMV (mock) and linearized at the 3'-end of poly A signal sequences by MluI restriction enzymes followed by purification. A similar approach was used to change the tyrosine residue to phenylalanine at positions 613 and 942 to create the double PI3K mutant construct (ΔPI3K). The hIRS-1 mutants have a FLAG epitope (DYKDDDDK (SEQ ID NO:6)+stop codon) added to the C-terminus by PCR. This strategy allows to distinguish the mutant protein from "wild type" hIRS-1 in stable transfected cell lines. The mutants are used to define the link between the IRS signal transduction pathway and activation of HAAH as a downstream effector gene and identify compounds to inhibit transduction along the pathway to inhibit growth of tumors characterized by HAAH overexpression. Antibodies or other compounds which bind to phosphorylation sites or inhibit phosphorylation at those sites are used to inhibit signal transduction and thus proliferation of HAA-overexpressing tumors.

[0145] Other embodiments are within the following claims.

What is claimed is:

1. A method for diagnosing a malignant neoplasm in a mammal, comprising contacting a bodily fluid from said mammal with an antibody which binds to an human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex.

2. The method of claim 1, wherein said neoplasm is derived from endodermal tissue.

3. The method of claim 1, wherein said neoplasm is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.

4. The method of claim 1, wherein said neoplasm is a cancer of the central nervous system (CNS).

5. The method of claim 1, wherein said bodily fluid is selected from the group consisting of a CNS-derived bodily fluid, blood, serum, urine, saliva, sputum, lung effusion, and ascites fluid.

6. The method of claim 1, wherein said antibody is a monoclonal antibody.

7. The method of claim 6, wherein said monoclonal antibody is FB50.

8. The method of claim 6, wherein said monoclonal antibody is selected from the group consisting of 5C7, 5E9, 19B, 48A, 74A, 78A, 86A.

9. A method for prognosis of a malignant neoplasm of a mammal, comprising

(a) contacting a bodily fluid from said mammal with an antibody which binds to an HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and detecting the antigen-antibody complex;

(b) quantitating the amount of complex to determine the level of HAAH in said fluid; and

(c) comparing the level of HAAH in said fluid with a normal control level of HAAH, wherein increasing levels of HAAH over time indicates an adverse prognosis.

10. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits expression of HAAH.

11. The method of claim 10, wherein said compound is a HAAH antisense nucleic acid.

12. The method of claim 10, wherein said compound is a ribozyme.

13. The method of claim 10, wherein said tumor is derived from endodermal tissue.

14. The method of claim 10, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.

15. The method of claim 10, wherein said tumor is a CNS tumor.

16. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits an enzymatic activity of HAAH.

17. The method of claim 16, wherein said enzymatic activity is hydroxylase activity.

18. The method of claim 16, wherein said compound is a dominant negative mutant of HAAH.

19. The method of claim 18, wherein said dominant negative mutant HAAH comprises a mutation in a catalytic domain of HAAH.

20. The method of claim 16, wherein said compound is an HAAH-specific intrabody.

21. The method of claim 16, wherein said compound is L-mimosine.

22. The method of claim 16, wherein said compound is a hydroxypyridone.

23. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits signal transduction through the IRS signal transduction pathway.

24. The method of claim 23, wherein said compound inhibits IRS phosphorylation.

25. The method of claim 23, wherein said compound inhibits binding of Fos or Jun to an HAAH promoter sequence.

26. A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits HAAH hydroxylation of a NOTCH polypeptide.

27. The method of claim 26, wherein said compound inhibits hydroxylation of an EGF-like repeat sequence in a NOTCH polypeptide.

28. A method of killing a tumor cell comprising contacting said tumor cell with cytotoxic agent linked to an HAAH-specific antibody.

29. A monoclonal antibody that binds to an epitope of HAAH.

30. The antibody of claim 29, wherein said epitope is within a catalytic site of HAAH.

31. The antibody of claim 29, wherein said monoclonal antibody is selected from the group consisting of 5C7, 5E9, 19B, 48A, 74A, 78A, 86A.

32. The antibody of claim 29, wherein said monoclonal antibody is selected from the group consisting of HA238A, HA221, HA239, HA241, HA329, or HA355.

33. A composition comprising a monoclonal antibody that binds to an epitope of HAAH linked to a cytotoxic agent, wherein said composition preferentially kills tumor cells compared to non-tumor cells.

34. A kit for diagnosis of a tumor in a mammal, comprising the antibody of claim 29.

35. The kit of claim 34, wherein said antibody is immobilized on a solid phase.

36. The kit of claim 35, wherein said solid phase is selected from a group consisting of an assay plate, an assay well, a nitrocellulose membrane, a bead, a dipstick, and a component of an elution column.

37. A method of determining whether a candidate compound inhibits HAAH enzymatic activity, comprising

- (a) providing a HAAH polypeptide;
 - (b) providing a polypeptide comprising an EGF-like domain;
 - (c) contacting said HAAH polypeptide or said NOTCH polypeptide with said candidate compound;
 - (d) determining hydroxylation of said polypeptide of step (b), wherein a decrease in hydroxylation in the presence of said candidate compound compared to that in the absence of said compound indicates that said compound inhibits HAAH enzymatic activity.
38. A method of determining whether a candidate compound inhibits HAAH activation of NOTCH, comprising
- (a) providing a cell expressing HAAH;
 - (b) contacting said cell with a candidate compound; and
 - (c) measuring translocation of activated NOTCH to the nucleus of said cell, wherein a decrease in translocation in the presence of said compound compared to that in the absence of said compound indicates that said compound HAAH activation of NOTCH.

* * * * *

专利名称(译)	恶性肿瘤的诊断和治疗		
公开(公告)号	US20020102263A1	公开(公告)日	2002-08-01
申请号	US09/903248	申请日	2001-07-11
[标]申请(专利权)人(译)	杰克R魔杖 DE LA MONTE SUZANNE中号 因斯NEDIM 卡尔森ROLF我		
申请(专利权)人(译)	WANDS JACK R. DE LA MONTE SUZANNE M. 因斯NEDIM 卡尔森ROLF I.		
当前申请(专利权)人(译)	罗德岛医院		
[标]发明人	WANDS JACK R DE LA MONTE SUZANNE M INCE NEDIM CARLSON ROLF I		
发明人	WANDS, JACK R. DE LA MONTE, SUZANNE M. INCE, NEDIM CARLSON, ROLF I.		
IPC分类号	A61K31/00 A61K31/4412 A61K31/45 A61K31/7088 A61K38/43 A61K39/395 A61K45/00 A61K48/00 A61P35/00 C07K14/47 C07K16/40 C12N9/02 C12N15/09 C12N15/113 C12P21/08 C12Q1/02 C12Q1 /26 G01N33/53 G01N33/573 G01N33/574 G01N33/577		
CPC分类号	A61K31/00 A61K31/4412 A61K2039/505 C07K14/47 C07K16/40 C12N9/0071 C12N15/1137 C12N2310 /111 C12N2310/315 C12N2799/027 C12Q1/26 C12Y114/11016 G01N33/574 G01N33/57484 G01N2500/00 G01N2500/10		
其他公开文献	US6783758		
外部链接	Espacenet USPTO		

Fig. 1

摘要(译)

本发明的特征在于一种通过使来自哺乳动物的体液与结合人天冬氨酰(天冬酰胺酰)β-羟化酶(HAAH)多肽的抗体接触以及通过抑制HAAH治疗恶性肿瘤的方法来诊断哺乳动物的恶性肿瘤的方法。

